<?xml version="1.0" encoding="iso-8859-1"?>
<!-- generator="FeedCreator 1.7.2" -->
<rss version="2.0">
    <channel>
        <title>The European Journal of Health Economics via MedWorm.com</title>
        <description>MedWorm.com provides a medical RSS filtering service. Over 6000 RSS medical sources are combined and output via different filters. This feed contains the latest items from the 'The European Journal of Health Economics' source.</description>
        <link><![CDATA[http://www.medworm.com/rss/search.php?qu=The+European+Journal+of+Health+Economics&t=The+European+Journal+of+Health+Economics&s=Search&f=source]]></link>
        <lastBuildDate>Sun, 21 Mar 2010 16:47:58 +0100</lastBuildDate>
        <item>
            <title>Modeling stroke management: a qualitative review of cost-effectiveness analyses</title>
            <link>http://www.medworm.com/index.php?rid=3386697&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0wn3l4j6460n4838%2F</link>
            <description>Conclusion&amp;nbsp;&amp;nbsp;The overall structure of the models reviewed was sound. However, they should include more systematically cardiovascular events
 and intracranial hemorrhage, as well as local epidemiological data. Further multi-way sensitivity analyses would help to identify
 key cost drivers with greater precision and robustness.
 
 
 
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-010-0228-4Authors
		Chantal Guilhaume, H. Lundbeck A/S Global Outcomes Research Division 37–45 Quai du Président Roosevelt 92445 Issy-les-Moulineaux Cedex FranceDelphine Saragoussi, H. Lundbeck A/S Global Outcomes Research Division 37–45 Quai du Président Roosevelt 92445 Issy-les-Moulineaux Cedex FranceJohn Cochran, H. Lundbeck A/S Global Outcomes Research Division 37–45 Qu...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3386697</comments>
            <pubDate>Thu, 18 Mar 2010 15:36:12 +0100</pubDate>
            <guid isPermaLink="false">3386697</guid>        </item>
        <item>
            <title>Utilities and disutilities for attributes of injectable treatments for type 2 diabetes</title>
            <link>http://www.medworm.com/index.php?rid=3361728&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy816ph728280644l%2F</link>
            <description>Discussion&amp;nbsp;&amp;nbsp;The three injection attributes were associated with small utility shifts in the expected directions. Dose frequency appears
 to be the most important of the three attributes from the patients’ perspective. The vignette-based SG approach was feasible
 and useful for assessing added utility or disutility of injection-related attributes associated with treatments for type 2
 diabetes.
 
 
 
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-010-0224-8Authors
		Kristina S. Boye, Eli Lilly and Company Indianapolis IN USALouis S. Matza, United BioSource Corporation Center for Health Outcomes Research 7101 Wisconsin Avenue, Suite 600 Bethesda MD 20814 USAKimberly N. Walter, United BioSource Corporation Center for Health Outcomes Research 7101 Wisconsi...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3361728</comments>
            <pubDate>Thu, 11 Mar 2010 18:14:43 +0100</pubDate>
            <guid isPermaLink="false">3361728</guid>        </item>
        <item>
            <title>Social health inequalities among older Europeans: the contribution of social and family background</title>
            <link>http://www.medworm.com/index.php?rid=3357714&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg304599r52508221%2F</link>
            <description>This article contributes to the identification of social
 determinants, which are important determinants of health and follows recommendations suggested to help ‘close the gap’ in
 various health inequities.
 
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-010-0229-3Authors
		Sandy Tubeuf, University of Leeds Academic Unit of Health Economics, Leeds Institute of Health Sciences Charles Thackrah Building, 101 Clarendon Road Leeds LS2 9LJ UKFlorence Jusot, Université Paris-Dauphine LEGOS Bureau A 522, Place du Maréchal de Lattre de Tassigny 75775 Paris Cedex 16 France
	

	
		Journal The European Journal of Health EconomicsOnline ISSN 1618-7601Print ISSN 1618-7598 (Source: The European Journal of Health Economics)</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3357714</comments>
            <pubDate>Wed, 10 Mar 2010 15:24:13 +0100</pubDate>
            <guid isPermaLink="false">3357714</guid>        </item>
        <item>
            <title>Generic substitution: micro evidence from register data in Norway</title>
            <link>http://www.medworm.com/index.php?rid=3357715&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F0327335l26545235%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The importance of prices, doctor and patient characteristics, and market institutions for the likelihood of choosing generic
 drugs instead of the more expensive original brand-name version are examined. Using an extensive dataset extracted from The
 Norwegian Prescription Database containing all prescriptions dispensed to individuals in February 2004 and 2006 on 23 different
 drugs (chemical substances) in Norway, we find strong evidence for the importance of both doctor and patient characteristics
 for the choice probabilities. The price difference between brand and generic versions and insurance coverage both affect generic
 substitution. Moreover, controlling for the retail chain affiliation of the dispensing pharmacy, we find that pharmacies play
 an important role...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3357715</comments>
            <pubDate>Wed, 10 Mar 2010 15:24:12 +0100</pubDate>
            <guid isPermaLink="false">3357715</guid>        </item>
        <item>
            <title>US health care reform: a work in progress</title>
            <link>http://www.medworm.com/index.php?rid=3315836&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh6t717361732w64h%2F</link>
            <description>Content Type Journal ArticleCategory EditorialDOI 10.1007/s10198-010-0225-7Authors
		Sean D. Sullivan, University of Washington Pharmaceutical Outcomes Research and Policy Program Seattle WA 98195 USA
	

	
		Journal The European Journal of Health EconomicsOnline ISSN 1618-7601Print ISSN 1618-7598 (Source: The European Journal of Health Economics)</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3315836</comments>
            <pubDate>Fri, 26 Feb 2010 09:42:50 +0100</pubDate>
            <guid isPermaLink="false">3315836</guid>        </item>
        <item>
            <title>Optimal deductibles for outpatient services</title>
            <link>http://www.medworm.com/index.php?rid=3313931&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Funp22m2031460ll3%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;This paper analyses the effect of absolute deductibles on the cost of insurance for outpatient services. Moreover, cost savings
 on retained losses are estimated. Sharing risks between the insured and the insurer reduces total expenditure for outpatient
 benefits by up to 35%. In particular, optimal deductibles are determined in their utilitarian sense: the maximum possible
 savings on medical expenses are computed from the ground up. As part of the study, the effect of age and gender on these savings
 is analysed. The analysis is based on data taken from the private medical insurance industry in Germany. Similarities and
 discrepancies with respect to results obtained in the RAND Health Insurance Experiment conducted in the United States from
 1971 to 1982 are highligh...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3313931</comments>
            <pubDate>Thu, 25 Feb 2010 06:54:50 +0100</pubDate>
            <guid isPermaLink="false">3313931</guid>        </item>
        <item>
            <title>Health care expenditures and gross domestic product: the Turkish case</title>
            <link>http://www.medworm.com/index.php?rid=3270861&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw6r13576l35172p1%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Our study examines the long-term relationship among per capita gross domestic product (GDP), per capita health expenditures
 and population growth rate in Turkey during the period 1984–2006, employing the Johansen multivariate cointegration technique.
 Related previous studies on OECD countries have mostly excluded Turkey—itself an OECD country. The only study on Turkey examines
 the period 1984–1998. However, after 1998, major events and policy changes that had a substantial impact on income and health
 expenditures took place in Turkey, including a series of reforms to restructure the health and social security system. In
 contrast to earlier findings in the literature, we find that the income elasticity of total health expenditures is less than
 one, which indi...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3270861</comments>
            <pubDate>Fri, 12 Feb 2010 07:09:30 +0100</pubDate>
            <guid isPermaLink="false">3270861</guid>        </item>
        <item>
            <title>Adverse selection in the health insurance market: some empirical evidence</title>
            <link>http://www.medworm.com/index.php?rid=3265902&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F34v76m5671777m73%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;This paper tests for the existence of adverse selection in the Brazilian individual health insurance market in 2003. The testing
 approach adapts that conceived by Chiappori and Salanié (Eur Econ Rev 41, 943–950, 1997; J Polit Econ 108, 56–78, 2000). After
 controlling for sex, age, income, number of dependents, occupational groups and schooling levels, the evidence favors adverse
 selection as indicated by a positive correlation between the coverage of the contract and occurrence of illnesses (as approximated
 by hospitalization) was not strong. The consideration of complex sampling in the probit estimations led to empirical evidence
 that does not indicate the presence of adverse selection, but which highlighted some interesting features of the relationship
 betw...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3265902</comments>
            <pubDate>Tue, 09 Feb 2010 17:45:15 +0100</pubDate>
            <guid isPermaLink="false">3265902</guid>        </item>
        <item>
            <title>Inequalities in the use of health services between immigrants and the native population in Spain: what is driving the differences?</title>
            <link>http://www.medworm.com/index.php?rid=3248409&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk722886444854246%2F</link>
            <description>In this study, we use the Oaxaca-Blinder decomposition technique
 to explore to what extent disparities in the probability of using medical care use can be attributed to differences in the
 determinants of use due to, e.g. a different demographic structure of the immigrant collective, rather than to a different
 effect of health care use determinants by nationality, holding all other factors equal. Our findings show that unexplained
 factors associated to immigrant status determine to a great extent disparities in the probability of using hospital, specialist
 and emergency services of immigrants relative to Spaniards, while individual characteristics, in particular self-reported
 health and chronic conditions, are much more important in explaining the differences in the probability of usi...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3248409</comments>
            <pubDate>Thu, 04 Feb 2010 18:11:49 +0100</pubDate>
            <guid isPermaLink="false">3248409</guid>        </item>
        <item>
            <title>Public health care providers and market competition: the case of Finnish occupational health services</title>
            <link>http://www.medworm.com/index.php?rid=3224653&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fcv221026448qpr03%2F</link>
            <description>Abstract
 Background&amp;nbsp;&amp;nbsp;As reforms in publicly funded health systems rely heavily on competition, it is important to know if and how public providers
 react to competition. In many European countries, it is empirically difficult to study public providers in different markets,
 but in Finnish occupational health services, both public and private for-profit and non-profit providers co-exist. We studied
 possible differences in public providers’ performance (price, intensity of services, service mix—curative medical services/prevention,
 productivity and revenues) according to the competitiveness of the market.
 
 
 
 Materials and methods&amp;nbsp;&amp;nbsp;The Finnish Institute of Occupational Health (FIOH) collected data on clients, services and personnel for 1992, 1995, 1997,
 2000 an...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3224653</comments>
            <pubDate>Thu, 28 Jan 2010 18:00:34 +0100</pubDate>
            <guid isPermaLink="false">3224653</guid>        </item>
        <item>
            <title>Analysis of physicians’ perspectives versus patients’ preferences: direct assessment and discrete choice experiments in the therapy of multiple myeloma</title>
            <link>http://www.medworm.com/index.php?rid=3224654&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F953v86877u671816%2F</link>
            <description>Conclusions&amp;nbsp;&amp;nbsp;Asking patients or physicians about the multiple myeloma patients’ treatment preferences, the combination of direct assessment
 and DCE proves to be a valid survey technique. Over a broad range of treatment attributes, the physicians’ perceptions of
 preferences were very close to those of multiple myeloma patients. Both the direct assessment of importance in order to rank
 the patient perceptions and the DCE provide important insights into the preference structure of patients with multiple myeloma.
 The findings can subsequently be used as a basis for tailoring health care services for multiple myeloma patients in reference
 to their preferences.
 
 
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-010-0218-6Authors
		Axel C. Mühlbacher,...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3224654</comments>
            <pubDate>Wed, 27 Jan 2010 20:29:29 +0100</pubDate>
            <guid isPermaLink="false">3224654</guid>        </item>
        <item>
            <title>HTA in Germany: very special and specific</title>
            <link>http://www.medworm.com/index.php?rid=3196675&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F944445n853144l87%2F</link>
            <description>Content Type Journal ArticleCategory EditorialDOI 10.1007/s10198-009-0216-8Authors
		Wolfgang Greiner, University of Bielefeld Department for Health Economics, School of Public Health Postfach 10 01 31 Bielefeld GermanyJ.-Matthias Graf von der Schulenburg, Leibniz University Hannover Centre for Health Economics Hannover Germany
	

	
		Journal The European Journal of Health EconomicsOnline ISSN 1618-7601Print ISSN 1618-7598 (Source: The European Journal of Health Economics)</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3196675</comments>
            <pubDate>Tue, 19 Jan 2010 17:43:40 +0100</pubDate>
            <guid isPermaLink="false">3196675</guid>        </item>
        <item>
            <title>The impact on schizophrenia-related hospital utilization and costs of switching to long-acting risperidone injections in Sweden</title>
            <link>http://www.medworm.com/index.php?rid=3192571&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F3614378105u00814%2F</link>
            <description>Conclusion&amp;nbsp;&amp;nbsp;A naturalistic mirror-image study found that switching to long-acting injectable risperidone led to sizeable reductions in
 inpatient resource use. These results coincide with the findings of other international studies.
 
 
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-009-0215-9Authors
		Michael Willis, The Swedish Institute for Health Economics Box 2127 220 02 Lund SwedenMarianne Svensson, The Swedish Institute for Health Economics Box 2127 220 02 Lund SwedenMickael Löthgren, Janssen-Cilag Sollentuna SwedenBo Eriksson, Janssen-Cilag Sollentuna SwedenAnders Berntsson, Psychiatry North East Stockholm SwedenUlf Persson, The Swedish Institute for Health Economics Box 2127 220 02 Lund Sweden
	

	
		Journal The European Journal of Health Econo...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3192571</comments>
            <pubDate>Mon, 18 Jan 2010 18:47:15 +0100</pubDate>
            <guid isPermaLink="false">3192571</guid>        </item>
        <item>
            <title>The sustainability of public health expenditures: evidence from the Canadian federation</title>
            <link>http://www.medworm.com/index.php?rid=3170443&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc87322w64w826212%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The fiscal sustainability of government health expenditures is defined as the gap between growth rates of spending and measures
 of the resource base. The results show that over the period 1965–2008, real per capita Canadian provincial government health
 spending has grown at rates that exceed growth in basic measures of the resource base such as per capita gross domestic product
 (GDP), per capita federal transfers and per capita provincial government revenues. Forecasts of future spending to 2035 using
 determinant regression and growth rate extrapolation techniques show that Canadian provincial government health spending is
 projected to continue rising in the future and its share of provincial GDP will rise. While the amount spent on health is
 ultimately a public...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3170443</comments>
            <pubDate>Mon, 11 Jan 2010 18:20:58 +0100</pubDate>
            <guid isPermaLink="false">3170443</guid>        </item>
        <item>
            <title>The effect of health care expenditure on sickness absence</title>
            <link>http://www.medworm.com/index.php?rid=3155500&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe455505140q6upq1%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Increased health care expenditure could be used to improve quality of care or reduce waiting time and could therefore be expected
 to affect the health and sickness absence of a population. Still, based on data from a panel of Swedish municipalities, public
 health care expenditure was found to have no, or only a negligible effect on absence due to sickness or disability. The same
 result was obtained when separate estimates were done for men and women and for absence due to sickness and disability.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-009-0213-yAuthors
		David Granlund, Umeå University Department of Economics 901 87 Umeå Sweden
	

	
		Journal The European Journal of Health EconomicsOnline ISSN 1618-7601Print ISSN 1618-7598 (Source:...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3155500</comments>
            <pubDate>Tue, 05 Jan 2010 17:00:01 +0100</pubDate>
            <guid isPermaLink="false">3155500</guid>        </item>
        <item>
            <title>Determinants of health care costs of HIV-positive patients in the Canary Islands, Spain</title>
            <link>http://www.medworm.com/index.php?rid=3155501&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F204643860q652653%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The aims of this study were to estimate medical expenditures on human immunodeficiency virus (HIV) treatment and to identify
 significant associated variables. We performed a retrospective multi-centre study in the Canary Islands using a sample of
 569 patients recruited at outpatient visits. The study examined demographic and clinical variables, health-related quality
 of life (HRQOL), and health care resources. Clinical data was obtained from medical records and patient interviews. Several
 empirical models for identifying the relationship between health care costs and independent variables were developed. The
 greatest expense came from pharmaceutical expenditure (82.1% of direct costs), while hospital costs only represented 4.6%
 of total expenditure. The data showe...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3155501</comments>
            <pubDate>Mon, 04 Jan 2010 18:20:13 +0100</pubDate>
            <guid isPermaLink="false">3155501</guid>        </item>
        <item>
            <title>Substituting inpatient for outpatient care: what is the impact on hospital costs and efficiency?</title>
            <link>http://www.medworm.com/index.php?rid=3126105&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw724184425205x55%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Substitution of inpatient for outpatient care is seen as a means to increase patient throughput and control costs. The purpose
 of this study was to assess the impact of increased outpatient care on hospital costs and efficiency using Finnish specialty-level
 data from years 2003–2006 to which we applied stochastic frontier analysis. The results reveal that outpatient services have
 a smaller impact on total costs than inpatient services. At the same time, increased outpatient activity appears to have an
 adverse effect on estimated cost efficiency. This counterintuitive finding is probably due to the low weight given to outpatient
 activities by the Diagnosis Related Groups (DRG) system. A common weighting for inpatient and outpatient services is required
 in order t...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3126105</comments>
            <pubDate>Sat, 26 Dec 2009 16:38:47 +0100</pubDate>
            <guid isPermaLink="false">3126105</guid>        </item>
        <item>
            <title>Colorectal cancer in Turkey: current situation and challenges for the future</title>
            <link>http://www.medworm.com/index.php?rid=3088359&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F9428441j6l821214%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Cancer is foremost among one of the major public health problems in Turkey. Projections for the year 2030 estimate that cancer
 will take the highest death toll for both males and females. In line with the dynamic health care reform process commencing
 in 2003, the national cancer policy of Turkey has also changed radically. Cancer became more visible as a public health problem
 and improvements have been made in early diagnosis and treatment of the disease. In addition, major steps have been taken
 to improve the cancer registry system in order to improve cancer statistics. Colorectal cancer (CRC) incidence is approximately
 7 per 100,000, with approximately 5,000 new cases and 3,200 deaths annually. Although cancer treatment expenditures are widely
 covered in Turkey,...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3088359</comments>
            <pubDate>Sat, 12 Dec 2009 14:17:38 +0100</pubDate>
            <guid isPermaLink="false">3088359</guid>        </item>
        <item>
            <title>Colorectal cancer in Italy: a review of current national and regional practice on screening and treatment</title>
            <link>http://www.medworm.com/index.php?rid=3088360&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp240w5710n66q1l4%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Colorectal cancer (CRC) is one of the most prevalent and deadly cancers in Italy. Its burden is expected to remain significant
 in the coming years, although it is mostly a preventable disease. Prevention and screening programmes will play an important
 role in the fight against CRC. A national formal screening programme was introduced in the 2003–2005 and 2005–2007 national
 health programmes, leaving the planning and implementation, respectively, to each region and local health unit. In 2007, screening
 programmes covered 46.6% of the eligible population, with a higher coverage in the North (71.6%) and in the Centre (52.1%)
 than in the South (7%). The majority of programmes used the guaiac faecal occult blood test (FOBT) as first-line test. Only
 few programmes u...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3088360</comments>
            <pubDate>Thu, 10 Dec 2009 15:07:36 +0100</pubDate>
            <guid isPermaLink="false">3088360</guid>        </item>
        <item>
            <title>Cancer management and reimbursement aspects in Germany: an overview demonstrated by the case of colorectal cancer</title>
            <link>http://www.medworm.com/index.php?rid=3088361&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F707175ut2474531v%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;This paper provides an overview of cancer management, particularly with respect to colorectal cancer (CRC), in Germany. The
 information presented reflects findings from the peer-review literature and government documentation, as well as interviews
 with cancer and CRC specialists. Topics such as epidemiology, expenditure, CRC screening, pharmaceutical and non-pharmaceutical
 treatment are discussed in this paper. Furthermore, insights into the German reimbursement system with regard to cancer management
 as well as regulatory aspects are presented.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-009-0194-xAuthors
		J.-Matthias von der Schulenburg, Leibniz University Hannover Hannover GermanyAnne Prenzler, Leibniz University Hannover Hannover Ge...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3088361</comments>
            <pubDate>Thu, 10 Dec 2009 15:07:35 +0100</pubDate>
            <guid isPermaLink="false">3088361</guid>        </item>
        <item>
            <title>Colorectal cancer in Mexico: should a middle income country invest in screening or in treatment?</title>
            <link>http://www.medworm.com/index.php?rid=3088363&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F6872t5k70w5mq81x%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Mexico, like many other middle-income countries, is experiencing a demographic and epidemiological transition resulting in
 an older population suffering from chronic diseases. At the present time, cancer is the second cause of death in the country.
 Until recently, cervical carcinoma was the most frequent type of cancer in the country, however, the incidence of breast,
 prostate and colon cancers is growing. The demand for health care and health expenditure represented by cancer treatment challenges
 the limited resources the country has, particularly as patients seek treatment in advanced stages of the disease. Interestingly
 enough, these types of cancers could be detected in the early stages with rather simple screening procedures. The purpose
 of this paper is to d...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3088363</comments>
            <pubDate>Thu, 10 Dec 2009 15:07:33 +0100</pubDate>
            <guid isPermaLink="false">3088363</guid>        </item>
        <item>
            <title>Geographic distribution of physicians in Portugal</title>
            <link>http://www.medworm.com/index.php?rid=3088362&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe8888074278g3k47%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The main goals of this paper are to (1) analyse the inequality in geographic distribution of physicians and its evolution,
 (2) estimate the determinants of physician density, and (3) assess the importance of competitive and agglomerative forces
 in location decisions. The analysis of the geographic distribution of physicians is based on the ratio of general practitioners
 (GPs) and specialists to 1,000 inhabitants. The inequality is measured using Gini indices, coefficients of variation, and
 physician-to-population ratios. The econometric models were estimated by ordinary least squares. The data used refer to 1996
 and 2007. The impact of the growing number of physicians, and therefore potential increased competition, on geographic distribution
 during the period stud...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3088362</comments>
            <pubDate>Thu, 10 Dec 2009 15:07:33 +0100</pubDate>
            <guid isPermaLink="false">3088362</guid>        </item>
        <item>
            <title>Adolescents alcohol-use and economic conditions: a multilevel analysis of data from a period with big economic changes</title>
            <link>http://www.medworm.com/index.php?rid=3088364&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F56xn8375k01w0p4v%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;This paper examines how the unemployment rate is related to adolescent alcohol use and experience of binge drinking during
 a time period characterized by big societal changes. The paper uses repeated cross-sectional adolescent survey data from a
 Swedish region, collected in 1988, 1991, 1995, 1998, 2002 and 2005, and merges this with data on local unemployment rates
 for the same time periods. Individual level frequency of alcohol use as well as experience of binge drinking is connected
 to local level unemployment rate to estimate the relationship using multilevel modeling. The model includes municipality effects
 controlling for time-invariant differences between municipalities as well as year fixed effects controlling for municipality-invariant
 changes over time in...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3088364</comments>
            <pubDate>Thu, 10 Dec 2009 15:07:32 +0100</pubDate>
            <guid isPermaLink="false">3088364</guid>        </item>
        <item>
            <title>Colorectal cancer care in Denmark: status and dilemmas</title>
            <link>http://www.medworm.com/index.php?rid=3088367&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F42022106h613077x%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The area of cancer care has received significant political attention in Denmark over the past decades. Colorectal cancer (CRC)
 has a relatively high burden of disease and high mortality. This paper describes the main initiatives to improve CRC treatment
 in Denmark. It highlights the introduction of national “cancer pathways” based on clinical guidelines. The pathways specify
 ideal patient pathways through the system and include standards for waiting times and care processes. The comprehensiveness
 and high quality of Danish patient registers will aid in the implementation. Yet a number of outstanding challenges are also
 identified. The most important include a shortage of nursing and medical specialists for cancer care, and issues of co-ordination
 between prima...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3088367</comments>
            <pubDate>Thu, 10 Dec 2009 15:07:31 +0100</pubDate>
            <guid isPermaLink="false">3088367</guid>        </item>
        <item>
            <title>Colorectal cancer management in Poland: current improvements and future challenges</title>
            <link>http://www.medworm.com/index.php?rid=3088366&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc4175j4175166125%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Colorectal cancer (CRC) is the second most commonly identified malignant neoplasm diagnosed in men (12% of total cancers)
 and women (11%) in Poland, while CRC mortality is second in men (10.1%) and third in women (11.2%). The main reasons for increasing
 incidence and mortality are an aging population and an increase in environmental and lifestyle factors which may lead to cancer.
 In Poland there is a lack of historical (regularly published and accessible) data on cancer morbidity and survival rates.
 The Oncology Centre published cancer data for the first time in February 2009 the 2006, which, also for the first time, embraced
 the entire country. Oncology data collection in Poland is based on a network of 16 Regional Cancer Registries reporting to
 the Polish Nation...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3088366</comments>
            <pubDate>Thu, 10 Dec 2009 15:07:31 +0100</pubDate>
            <guid isPermaLink="false">3088366</guid>        </item>
        <item>
            <title>The challenge of colorectal cancer prevention in Spain</title>
            <link>http://www.medworm.com/index.php?rid=3088365&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl71g321815586615%2F</link>
            <description>Abstract
 &amp;nbsp;&amp;nbsp;Colorectal cancer (CRC) is the leading cause of all new cancer cases and the second major cause for all cancer deaths in Spain.
 CRC survival has improved over the past few decades and is now higher than the 5-years European average, but this is associated
 with improved treatment than to early detection. A number of screening pilot programs have been completed in various regions,
 likely leading to national implementation in the future. Treatment guidelines have been developed and implemented to set standards
 and reduce practice variability. Newer treatments are available, including laparoscopic surgery, adjuvant chemotherapy and
 the use of targeted treatments. Specific programs are in place for rural patients, as well as programs to reduce waiting times.
 Overall,...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3088365</comments>
            <pubDate>Thu, 10 Dec 2009 15:07:31 +0100</pubDate>
            <guid isPermaLink="false">3088365</guid>        </item>
        <item>
            <title>Colorectal cancer management in the United Kingdom: current practice and challenges</title>
            <link>http://www.medworm.com/index.php?rid=3088368&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk33288h6071h24k1%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;This paper explores the current situation of colorectal cancer (CRC) management in the UK. Colorectal cancer is the third
 leading cause of cancer death in the UK, and the second and third leading cause of new cancer cases in women and men, respectively.
 These figures have increased over the past decade and, coupled with poorer survival rates compared to the European average
 and an ageing population, have recently led to the implementation of national screening in 2007–2009. Staffing adjustments
 are being made in preparation for national CRC-related demands, and national treatment guidelines are currently being revised.
 Access to new targeted treatments, however, is very limited due to negative NICE guidance and access is granted to only a
 select few. Targets hav...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3088368</comments>
            <pubDate>Thu, 10 Dec 2009 15:07:30 +0100</pubDate>
            <guid isPermaLink="false">3088368</guid>        </item>
        <item>
            <title>Colorectal cancer in France</title>
            <link>http://www.medworm.com/index.php?rid=3088369&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F3628741220648884%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Colorectal cancer (CRC) presents a substantial health burden in France, as the third 
 cause of new cancer cases after breast and prostate cancers and the second cancer 
 mortality cause representing nearly 12% of cancer deaths and almost 10% of annual 
 life year loss due to cancer. Its prognosis has dramatically improved since the 
 1970s due to earlier diagnosis and an increase in the number of cases eligible 
 for surgery. The first cancer plan implemented for the period 2003–2006 led to 
 further improvements via, amongst others, implementing a national cancer 
 institute (INCA), developing research, improving the quality of care and facilitating 
 access to innovative treatments. The second cancer plan (2009–2013) aims to 
 expand the scope of the existing can...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3088369</comments>
            <pubDate>Thu, 10 Dec 2009 15:07:29 +0100</pubDate>
            <guid isPermaLink="false">3088369</guid>        </item>
        <item>
            <title>The disease burden of colorectal cancer in Hungary</title>
            <link>http://www.medworm.com/index.php?rid=3088370&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fautmv6t721p78n6g%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The aim of the paper is to give an overview of the epidemiology, treatment pattern and quality, as well as policy issues and
 disease burden of colorectal cancer (CRC) in Hungary. Colorectal cancer is the second most common cause of cancer-related
 death in both males and females in Hungary. The Hungarian Cancer Registry collects data on the epidemiological characteristics
 of CRC. Two pilot programmes (1997/1998 and 2003/2004) were conducted for population-based screening of CRC using both immunological
 and guaiac faecal occult blood testing (FOBT). The National Health Insurance Fund Administration (NHIFA) spends altogether
 &amp;#8364;&amp;nbsp;38.9 million a year on the treatment of CRC. It is hoped that the introduction of an accepted and cost-effective screening
 programm...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3088370</comments>
            <pubDate>Thu, 10 Dec 2009 15:07:27 +0100</pubDate>
            <guid isPermaLink="false">3088370</guid>        </item>
        <item>
            <title>Colorectal cancer in Russia</title>
            <link>http://www.medworm.com/index.php?rid=3088371&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh5563481644x316g%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Using peer-reviewed publications and official government documents, this paper covers three important issues concerning colorectal
 cancer (CRC) in Russia: (1) CRC epidemiology, (2) screening for CRC, (3) medical care for patients with CRC. Colon and rectal
 cancer are registered separately in Russia. When colon and rectal cancers are considered together, CRC is the second cause
 of cancer death for women (after breast cancer) and the third for men (after lung and stomach cancer), while both incidence
 and mortality have increased over the past decade. About a quarter of all new colon and rectal cancer cases are diagnosed
 at Stage IV and one-third of patients with newly diagnosed disease die in the first year after diagnosing, however, poor data
 collection and collati...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3088371</comments>
            <pubDate>Thu, 10 Dec 2009 15:07:25 +0100</pubDate>
            <guid isPermaLink="false">3088371</guid>        </item>
        <item>
            <title>The status of colorectal cancer care in the Netherlands: past, present and future</title>
            <link>http://www.medworm.com/index.php?rid=3088374&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff08gu564542p7701%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Cancer is now the primary cause of death in the Netherlands, with colorectal cancer (CRC) being responsible for a significant
 portion of cancer incidence (14%) and mortality (11.8%) in men and women. An aging population and the possibility of national
 CRC screening, currently under discussion, will likely increase this burden. Despite switching in 2006 to obligatory subsidized
 private health insurance, health expenditure continues to rise, along with increased cancer and drug expenditures. Despite
 rising drug expenditures, new targeted biological treatments are available under centrally subsidized provisions. CRC treatment
 guidelines are available, published online, regularly updated, and monitored for quality purposes. There are concerns regarding
 waiting times f...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3088374</comments>
            <pubDate>Thu, 10 Dec 2009 15:07:21 +0100</pubDate>
            <guid isPermaLink="false">3088374</guid>        </item>
        <item>
            <title>The burden of colorectal cancer: prevention, treatment and quality of services</title>
            <link>http://www.medworm.com/index.php?rid=3088373&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ffxng32hh24705323%2F</link>
            <description>Content Type Journal ArticleCategory EditorialDOI 10.1007/s10198-009-0200-3Authors
		Panos Kanavos, London School of Economics Department of Social Policy and LSE Health Houghton Street London WC2A 2AE UKWillemien Schurer, London School of Economics Department of Social Policy and LSE Health Houghton Street London WC2A 2AE UK
	

	
		Journal The European Journal of Health EconomicsOnline ISSN 1618-7601Print ISSN 1618-7598 (Source: The European Journal of Health Economics)</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3088373</comments>
            <pubDate>Thu, 10 Dec 2009 15:07:21 +0100</pubDate>
            <guid isPermaLink="false">3088373</guid>        </item>
        <item>
            <title>Colorectal cancer in Portugal</title>
            <link>http://www.medworm.com/index.php?rid=3088372&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff166t2vn1w3183vt%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Increasing diagnosis and deaths caused by colorectal cancer (CRC) warrant closer examination of affected patients and focus
 on management of CRC in Portugal. In order to assess the extent and quality of the information available in Portugal, we first
 analyse Portuguese cancer registries and then the management of CRC by discussing the diagnostic process and medical care
 provided, especially pharmaceuticals. Other cancer indications are mentioned in order to illustrate current approaches of
 cancer in Portugal. Current national data on cancer patients are scarce and there are divergencies in methods of data collection
 and treatment amongst regional cancer registries. However, the available data is sufficient enough to understand the dimension
 of CRC, with age-standa...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3088372</comments>
            <pubDate>Thu, 10 Dec 2009 15:07:21 +0100</pubDate>
            <guid isPermaLink="false">3088372</guid>        </item>
        <item>
            <title>Colocteral cancer management and prevention policies in Greece</title>
            <link>http://www.medworm.com/index.php?rid=3088376&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff88nv2684929k6uk%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Despite lower cancer mortality rates in Greece compared to other European countries, colorectal cancer (CRC) is the third
 most important cause of cancer mortality. Given the significant economic and societal impact of CRC in Greece, this paper
 focuses on CRC data resources, disease management and the existing prevention policies. Numerous initiatives have taken place
 for the collection of data and the creation of cancer registries, however, they currently remain incomplete. Despite universal
 access of the Greek population to health services provision, structural problems of the national health system have imposed
 organisational barriers to the geographical distribution of health resources. National invitational CRC screening programmes
 focusing on early detection ...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3088376</comments>
            <pubDate>Thu, 10 Dec 2009 15:07:17 +0100</pubDate>
            <guid isPermaLink="false">3088376</guid>        </item>
        <item>
            <title>The dynamics of colorectal cancer management in 17 countries</title>
            <link>http://www.medworm.com/index.php?rid=3088375&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff6297253512r0345%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;This paper discusses the current care management arrangements for colorectal cancer (CRC) in 16 OECD countries plus the Russian
 Federation by analysing data sources, the uptake of screening and surveillance, the available capacity in endoscopy services,
 the treatment pathways in medical treatment, as well as the type and availability of pharmaceutical care. The paper highlights
 significant variations in practice across the 17 countries. Common themes emerge from each of these practices and standards
 in terms of political interest in policies and awareness of CRC (both of which need to be enhanced), affordability (in terms
 of scarcity of resources in some countries and out-of-pocket payments for parts of the overall treatment process), access
 (in terms of the signi...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3088375</comments>
            <pubDate>Thu, 10 Dec 2009 15:07:17 +0100</pubDate>
            <guid isPermaLink="false">3088375</guid>        </item>
        <item>
            <title>The macroeconomic impact of pandemic influenza: estimates from models of the United Kingdom, France, Belgium and The Netherlands</title>
            <link>http://www.medworm.com/index.php?rid=3081682&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp337u8m136561114%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The 2003 outbreak of severe acute respiratory syndrome (SARS) showed that infectious disease outbreaks can have notable macroeconomic
 impacts. The current H1N1 and potential H5N1 flu pandemics could have a much greater impact. Using a multi-sector single country
 computable general equilibrium model of the United Kingdom, France, Belgium and The Netherlands, together with disease scenarios
 of varying severity, we examine the potential economic cost of a modern pandemic. Policies of school closure, vaccination
 and antivirals, together with prophylactic absence from work are evaluated and their cost impacts are estimated. Results suggest
 GDP losses from the disease of approximately 0.5–2% but school closure and prophylactic absenteeism more than triples these
 effec...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3081682</comments>
            <pubDate>Tue, 08 Dec 2009 19:48:11 +0100</pubDate>
            <guid isPermaLink="false">3081682</guid>        </item>
        <item>
            <title>Cost-effectiveness analysis of rituximab treatment in patients in Germany with rheumatoid arthritis after etanercept-failure</title>
            <link>http://www.medworm.com/index.php?rid=3066057&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk507390l43314122%2F</link>
            <description>Conclusion&amp;nbsp;&amp;nbsp;Rituximab appears to be a cost-effective treatment alternative compared to the switch between TNF-inhibitors as second line
 biological treatment in patients with active RA having failed etanercept.
 
 
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-009-0205-yAuthors
		Sonja Merkesdal, Hannover Medical School Division of Clinical Immunology and Rheumatology, Working Group for Health Economics and Clinical Epidemiology Carl-Neuberg-Strasse 1 OE 6830 30625 Hannover GermanyTimm Kirchhoff, Hannover Medical School Division of Clinical Immunology and Rheumatology, Working Group for Health Economics and Clinical Epidemiology Carl-Neuberg-Strasse 1 OE 6830 30625 Hannover GermanyDiane Wolka, Roche Pharma Grenzach-Wyhlen GermanyGunter Ladinek, Roche Ph...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3066057</comments>
            <pubDate>Fri, 04 Dec 2009 21:17:19 +0100</pubDate>
            <guid isPermaLink="false">3066057</guid>        </item>
        <item>
            <title>Cost effectiveness of palivizumab in Spain: an analysis using observational data</title>
            <link>http://www.medworm.com/index.php?rid=3066058&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F352p782854237506%2F</link>
            <description>Conclusion&amp;nbsp;&amp;nbsp;Palivizumab provides a cost-effective method of prophylaxis against severe RSV disease requiring hospitalisation among preterm
 infants in Spain.
 
 
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-009-0206-xAuthors
		Mark J. Nuijten, IMTA, Erasmus University Rotterdam The NetherlandsWolfgang Wittenberg, Abbott GmbH &amp; Co, KG Global Health Economics and Outcomes Research Knollstrasse P.O. Box 21 08 06 6700 Ludwigshafen Germany
	

	
		Journal The European Journal of Health EconomicsOnline ISSN 1618-7601Print ISSN 1618-7598 (Source: The European Journal of Health Economics)</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3066058</comments>
            <pubDate>Fri, 04 Dec 2009 21:17:18 +0100</pubDate>
            <guid isPermaLink="false">3066058</guid>        </item>
        <item>
            <title>The direct, indirect and intangible costs of visual impairment caused by neovascular age-related macular degeneration</title>
            <link>http://www.medworm.com/index.php?rid=3022119&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F32128654qu362886%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Neovascular age-related macular degeneration (nvAMD) is a chronic, progressive disease of the central retina, and its prevalence
 is expected to rise with the ageing population. Using a bottom-up approach based on retrospective data, this cross-sectional
 study estimated average annual direct costs of nvAMD to be £4,047, and average annual indirect costs to be £449. An attempt
 to measure intangible costs through willingness-to-pay yielded a lower response rate and estimated intangible costs to be
 11.5% of monthly income. Direct costs were significantly higher for male participants, for those who have mild or moderate
 visual impairment in both eyes, and for those who have been diagnosed for a shorter time. The findings of this study suggest
 that the availability of...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=3022119</comments>
            <pubDate>Sat, 21 Nov 2009 09:09:34 +0100</pubDate>
            <guid isPermaLink="false">3022119</guid>        </item>
        <item>
            <title>Health costs in patients treated for depression, in patients with depressive symptoms treated for another chronic disorder, and in non-depressed patients: a two-year prospective cohort study in anthroposophic outpatient settings</title>
            <link>http://www.medworm.com/index.php?rid=2991948&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft372m50463r4768w%2F</link>
            <description>This study underlines the importance of depression
 for health costs, and suggests that treatment of depression could be associated with long-term cost reductions.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-009-0203-0Authors
		Harald J. Hamre, Institute for Applied Epistemology and Medical Methodology Zechenweg 6 79111 Freiburg GermanyClaudia M. Witt, Charité University Medical Centre Institute of Social Medicine, Epidemiology, and Health Economics Berlin GermanyAnja Glockmann, Institute for Applied Epistemology and Medical Methodology Zechenweg 6 79111 Freiburg GermanyRenatus Ziegler, Society for Cancer Research Arlesheim SwitzerlandGunver S. Kienle, Institute for Applied Epistemology and Medical Methodology Zechenweg 6 79111 Freiburg GermanyStefan N. Willic...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2991948</comments>
            <pubDate>Thu, 12 Nov 2009 18:40:31 +0100</pubDate>
            <guid isPermaLink="false">2991948</guid>        </item>
        <item>
            <title>Health care utilisation and immigration in Spain</title>
            <link>http://www.medworm.com/index.php?rid=2971753&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa2508h5166v15178%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The aim of this work was to analyse the use of health care services by immigrants in Spain. Using a nationally representative
 health survey from 2006–2007 and negative binomial and hurdle models, it was found that there is no statistically significant
 difference in the patterns of visits to general practitioners and hospital stays between migrants and natives in Spain. However,
 immigrants have a lower access to specialists and visit emergency rooms with a higher frequency than nationals.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-009-0204-zAuthors
		José-Ignacio Antón, University of Salamanca Department of Applied Economics 37007 Salamanca SpainRafael Muñoz de Bustillo, University of Salamanca Department of Applied Economics 37007 S...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2971753</comments>
            <pubDate>Fri, 06 Nov 2009 18:58:50 +0100</pubDate>
            <guid isPermaLink="false">2971753</guid>        </item>
        <item>
            <title>The challenge of corporatisation: the experience of Portuguese public hospitals</title>
            <link>http://www.medworm.com/index.php?rid=2930089&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F54n7qp1778126657%2F</link>
            <description>This study evaluates hospital performance by calculating
 two efficiency measures associated with two categories of inputs. The first efficiency measures the costs associated with
 hospital production lines and the number of beds (representing fixed capacity) as inputs. The annual costs generated by the
 hospitals in the consumption of capital and work (direct and indirect costs) are used. A second measure of efficiency is calculated
 separately. This measure includes in the inputs the number of beds as well as the human resources available (number of doctors,
 number of nurses and other personnel) in each hospital. With regard to output, the variables that best reflect the hospital
 services rendered were considered: number of inpatient days, patients discharged, outpatient visits, emerge...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2930089</comments>
            <pubDate>Fri, 23 Oct 2009 18:53:59 +0100</pubDate>
            <guid isPermaLink="false">2930089</guid>        </item>
        <item>
            <title>Cost-effectiveness of infliximab for the treatment of acute exacerbations of ulcerative colitis</title>
            <link>http://www.medworm.com/index.php?rid=2919018&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr4v12p1ju8703180%2F</link>
            <description>Conclusion&amp;nbsp;&amp;nbsp;Infliximab induction regimen appears to be a cost-effective treatment option for UC patients hospitalised with an acute exacerbation.
 
 
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-009-0199-5Authors
		Yogesh Suresh Punekar, Schering-Plough Ltd Welwyn Garden City AL7 1TW UKNeil Hawkins, Oxford Outcomes Oxford UK
	

	
		Journal The European Journal of Health EconomicsOnline ISSN 1618-7601Print ISSN 1618-7598 (Source: The European Journal of Health Economics)</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2919018</comments>
            <pubDate>Wed, 21 Oct 2009 09:06:10 +0100</pubDate>
            <guid isPermaLink="false">2919018</guid>        </item>
        <item>
            <title>Optimal savings and health spending over the life cycle</title>
            <link>http://www.medworm.com/index.php?rid=2864798&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff55149q68m2525q1%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;This paper investigates the relationship between saving and health spending in a two-period overlapping generations economy.
 Individuals work in the first period of life and live in retirement in old age. Health spending is an activity that increases
 quality of life and longevity. Empirical evidence shows that both health spending and saving behave as luxury goods but their
 behaviour differs markedly according to the level of per capita GDP. The share of saving on GDP has a concave shape with respect
 to per capita GDP, whereas the share of health spending on GDP increases more than proportionally with respect to per capita
 GDP. The ratio of saving to spending is nonlinear with respect to income, i.e. first increasing and then decreasing. This
 ratio, in the propose...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2864798</comments>
            <pubDate>Thu, 01 Oct 2009 18:32:27 +0100</pubDate>
            <guid isPermaLink="false">2864798</guid>        </item>
        <item>
            <title>Onset of disability and life satisfaction: evidence from the German Socio-Economic Panel</title>
            <link>http://www.medworm.com/index.php?rid=2850287&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb277u4412t8u0154%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;This paper analyses the effect of the onset of disability on the well-being of individuals. In particular, we are interested
 in studying whether people can adapt to disability over time after its onset. Using longitudinal data from the German Socio-Economic
 Panel (GSOEP) for the period 1984–2006, we estimate life satisfaction equations using a fixed-effects model for working-age
 males (aged 21–58). The results show that disability has a significant negative effect on life satisfaction, but, in time,
 hedonic adaptation will return disabled males to life satisfaction levels registered by those who have not become disabled.
 These findings contribute to supporting the idea within psychology literature that individuals bounce back from painful events
 or adversities...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2850287</comments>
            <pubDate>Tue, 29 Sep 2009 16:54:31 +0100</pubDate>
            <guid isPermaLink="false">2850287</guid>        </item>
        <item>
            <title>Expenditures of the German statutory health insurance system for patients suffering from acute coronary syndrome and treated with percutaneous coronary intervention</title>
            <link>http://www.medworm.com/index.php?rid=2833800&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft870v216048g32n5%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Patients with acute coronary syndrome (ACS) are in need of cost-intensive treatment involving different aspects of the German
 Health System. Percutaneous coronary intervention (PCI) is the treatment of choice for a large proportion of cases. In the
 present study, an analysis of the cost impact of ACS with focus on PCI therapy was conducted across-the-board for the German
 Health System. Results indicated that 85% of all costs arising from treatment of ACS with a trial of PCI are due to in-patient
 care. Projection of results onto the entire insurant collective of the statutory health system estimated a total of &amp;#8364;954,995,603—a
 proportional 0.7% of all expenditure by statutory health insurances in 2005.
 
	Content Type Journal ArticleCategory Original PaperDOI ...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2833800</comments>
            <pubDate>Wed, 23 Sep 2009 06:01:50 +0100</pubDate>
            <guid isPermaLink="false">2833800</guid>        </item>
        <item>
            <title>Health impairments and labour market outcomes</title>
            <link>http://www.medworm.com/index.php?rid=2827212&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F675651422r5005g9%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Our analysis is based on the 2008 Athens Area Study and exploits detailed information regarding health impairments and labour
 market outcomes for Greek males. Distinguishing between healthy and heath-impaired employees who have or do not have work
 limitations, the unobserved productivity effect of health is separated from discrimination. We then estimate a regression
 model that includes terms to correct for employment selection and endogenous stratification of self-reported health condition.
 A penalty for productivity limitation exists. Evidence of wage discrimination is also found. Both findings are statistically
 significant and highlight the necessity for instituting active policies against unequal treatment.
 
	Content Type Journal ArticleCategory Original Paper...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2827212</comments>
            <pubDate>Mon, 21 Sep 2009 16:06:24 +0100</pubDate>
            <guid isPermaLink="false">2827212</guid>        </item>
        <item>
            <title>Health insurance for the poor: impact on catastrophic and out-of-pocket health expenditures in Mexico</title>
            <link>http://www.medworm.com/index.php?rid=2812014&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F448753606647j601%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The goal of Seguro Popular (SP) in Mexico was to improve the financial protection of the uninsured population against excessive
 health expenditures. This paper estimates the impact of SP on catastrophic health expenditures (CHE), as well as out-of-pocket
 (OOP) health expenditures, from two different sources. First, we use the SP Impact Evaluation Survey (2005–2006), and compare
 the instrumental variables (IV) results with the experimental benchmark. Then, we use the same IV methods with the National
 Health and Nutrition Survey (ENSANUT 2006). We estimate naïve models, assuming exogeneity, and contrast them with IV models
 that take advantage of the specific SP implementation mechanisms for identification. The IV models estimated included two-stage
 least squares ...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2812014</comments>
            <pubDate>Wed, 16 Sep 2009 18:57:30 +0100</pubDate>
            <guid isPermaLink="false">2812014</guid>        </item>
        <item>
            <title>Copayments for ambulatory care in Germany: a natural experiment using a difference-in-difference approach</title>
            <link>http://www.medworm.com/index.php?rid=2812015&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fut5121252871u291%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;In response to increasing health expenditures and a high number of physician visits, the German government introduced a copayment
 for ambulatory care in 2004 for individuals with statutory health insurance (SHI). Because persons with private insurance
 were exempt from the copayments, this health-care reform can be regarded as a natural experiment. We used a difference-in-difference
 approach to examine whether the new copayment effectively reduced the overall demand for physician visits and to explore whether
 it acted as a deterrent to vulnerable groups, such as those with low income or chronic conditions. We found that there was
 no significant reduction in the number of physician visits among SHI members compared to our control group. At the same time,
 we did not ...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2812015</comments>
            <pubDate>Wed, 16 Sep 2009 18:57:29 +0100</pubDate>
            <guid isPermaLink="false">2812015</guid>        </item>
        <item>
            <title>Eliciting health state utilities from the general public for severe chronic pain</title>
            <link>http://www.medworm.com/index.php?rid=2701506&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fgu64n2407033p211%2F</link>
            <description>Conclusion&amp;nbsp;&amp;nbsp;The study shows a clear decrement in utility moving from different severity levels of severe chronic pain.
 
 
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-009-0178-xAuthors
		S. Eldabe, The James Cook University Hospital Department of Pain and Anaesthesia Middlesbrough UKA. Lloyd, Former United BioSource Corporation London UKL. Verdian, Eisai Global Health Economics and Outcomes Research London UKM. Meguro, United BioSource Corporation London UKG. Maclaine, Eisai Global Health Economics and Outcomes Research London UKS. Dewilde, Former United BioSource Corporation London UK
	

	
		Journal The European Journal of Health EconomicsOnline ISSN 1618-7601Print ISSN 1618-7598 (Source: The European Journal of Health Economics)</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2701506</comments>
            <pubDate>Wed, 12 Aug 2009 22:34:58 +0100</pubDate>
            <guid isPermaLink="false">2701506</guid>        </item>
        <item>
            <title>An economic model for the prevention of MRSA infections after surgery: non-glycopeptide or glycopeptide antibiotic prophylaxis?</title>
            <link>http://www.medworm.com/index.php?rid=2687468&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq801u38783x72350%2F</link>
            <description>Conclusions&amp;nbsp;&amp;nbsp;The indicative model provides a framework for evaluation. More work is needed to understand the impact of antibiotic resistance
 over time in these currently effective antibiotics.
 
 
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-009-0175-0Authors
		Rachel A. Elliott, University of Nottingham Division of Social Research in Medicines and Health, School of Pharmacy Nottingham NG7 2RD UKHelen L. A. Weatherly, University of York Centre for Health Economics Heslington York YO10 5DD UKNeil S. Hawkins, University of York Centre for Health Economics Heslington York YO10 5DD UKGillian Cranny, University of York Centre for Reviews and Dissemination Heslington York YO10 5DD UKDuncan Chambers, University of York Centre for Reviews and Dissemination He...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2687468</comments>
            <pubDate>Sun, 09 Aug 2009 07:11:16 +0100</pubDate>
            <guid isPermaLink="false">2687468</guid>        </item>
        <item>
            <title>The Irish ‘health basket’: a basket case?</title>
            <link>http://www.medworm.com/index.php?rid=2681016&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj47t070m6w733p0q%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The Irish health care system is typically described as complex and inequitable and yet the source of the complexity is difficult
 to identify. This paper examines and documents the way in which the structure of the Irish system is complicated when compared
 with other countries. Analysis is conducted in the context of the ‘health basket’ framework. A health basket describes which
 health care services, and which individuals, are covered by public funding, and to what extent. The Irish health basket is
 outlined along three dimensions of breadth, depth, and height, and compared with the health baskets of the United Kingdom,
 Canada, Australia, Sweden and France. Results indicate that it is in the combination of breadth and height that distinguishes
 the Irish basket ...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2681016</comments>
            <pubDate>Tue, 04 Aug 2009 21:20:19 +0100</pubDate>
            <guid isPermaLink="false">2681016</guid>        </item>
        <item>
            <title>Principal agent relationships and the efficiency of hospitals</title>
            <link>http://www.medworm.com/index.php?rid=2681015&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft0w5510266448q48%2F</link>
            <description>This study used principal
 agent theory to explain differences in efficiency between hospitals. Two agency issues are examined: (1) quality of care in
 the relationship between hospital and patient, and (2) internal organisation, i.e. the relationship between the hospital and
 its main departments. It was found that efficiency and quality go together. This implies that the potential harmful information
 asymmetry between hospitals and patients does not appear to be a major problem, because increasing efficiency does not seem
 to reduce quality. Further, we find no relationship between the efficiency of departments and the efficiency of the entire
 hospital. The interest of hospital departments is currently not in line with the interests of the entire hospital.
 
	Content Type Journal Artic...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2681015</comments>
            <pubDate>Tue, 04 Aug 2009 21:20:19 +0100</pubDate>
            <guid isPermaLink="false">2681015</guid>        </item>
        <item>
            <title>The welfare costs of HIV/AIDS in Eastern Europe: an empirical assessment using the economic value-of-life approach</title>
            <link>http://www.medworm.com/index.php?rid=2681017&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa6v61786k6001336%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Based on the aggregation of individual willingness-to-pay for a statistical life, we calibrate an inter-temporal optimisation
 model to determine the aggregate welfare loss from HIV/AIDS in 25 Eastern European countries. Assuming a discount rate of
 3%, we find a total welfare loss for the whole region that exceeds US&amp;nbsp;$800&amp;nbsp;billion, approximately 10% of the region’s annual
 GDP between 1995 and 2001. Although prevalence and incidence rates diverge sharply between countries—with central Europe far
 less affected than major countries in the Commonwealth of Independent States and the Baltics—the epidemic is likely to spread
 to all countries unless a coherent strategy of prevention and treatment is backed up by substantial increases in healthcare
 investment...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2681017</comments>
            <pubDate>Tue, 04 Aug 2009 21:20:18 +0100</pubDate>
            <guid isPermaLink="false">2681017</guid>        </item>
        <item>
            <title>Pharmaceutical penetration of new drug and pharmaceutical market structure in Taiwan: hospital-level prescription of thiazolidinediones for diabetes</title>
            <link>http://www.medworm.com/index.php?rid=2666455&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg18636307270g160%2F</link>
            <description>In conclusion, hospital characteristics and volume of services determined
 the concentration of pharmaceuticals at the institution level, reflecting the heterogeneous competition between pharmaceutical
 companies within each hospital. Institution-level pharmaceutical concentration influences the adoption and penetration of
 new drugs.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-009-0174-1Authors
		Yi-Wen Tsai, National Health Research Institutes Institute of Population Health Sciences 35 Keyan Road Zhunan Miaoli 350 TaiwanYu-Wen Wen, National Health Research Institutes Institute of Population Health Sciences 35 Keyan Road Zhunan Miaoli 350 TaiwanWeng-Foung Huang, National Yang-Ming University Institute of Health and Welfare Policy No. 155, Sec. 2, Linong St. Ta...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2666455</comments>
            <pubDate>Sun, 02 Aug 2009 06:26:18 +0100</pubDate>
            <guid isPermaLink="false">2666455</guid>        </item>
        <item>
            <title>A case study of ex ante, value-based price and reimbursement decision-making: TLV and rimonabant in Sweden</title>
            <link>http://www.medworm.com/index.php?rid=2662248&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff0845571659m2653%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Value-based pricing (VBP) is a method of setting prices for products based on perceived benefits to the consumer. When information
 is symmetric and freely available and agency is perfect, VBP is efficient and desirable. Because of substantial information
 asymmetries, medical insurance distortions, and the prescribing monopoly of physicians, VBP is rare for prescription drugs,
 though a number of countries have recently moved in this direction. Because the potential benefits can be sizable, it is high
 time for a review of actual VBP-based decision-making in practice. Sweden, with its pharmaceutical benefits board (TLV), was
 an early adopter of VBP decision-making. We illustrate actual decision-making, thus, using the case of Acomplia® for the treatment of obesity in...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2662248</comments>
            <pubDate>Tue, 28 Jul 2009 18:28:57 +0100</pubDate>
            <guid isPermaLink="false">2662248</guid>        </item>
        <item>
            <title>The impact of reference pricing on switching behaviour and healthcare utilisation: the case of statins in Germany</title>
            <link>http://www.medworm.com/index.php?rid=2662249&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F75rx4453j0087217%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;This paper analyses (1) the impact of the inclusion of statins in the German reference pricing scheme in 2005 on the statin
 market, and (2) the effect of switching behaviour subsequent to the policy change on healthcare utilisation and costs. Patients
 with prescriptions for statins in 2004 were observed for 1&amp;nbsp;year before and 1&amp;nbsp;year after the policy change, which went into
 effect on 1 January 2005. Data on outpatient and inpatient visits, pharmaceutical consumption, and cost to the sickness fund
 were collected from a sickness fund with more than 5.8&amp;nbsp;million insured members in 2005. Compared to patients who were not
 affected by the policy change, patients treated previously with atorvastatin experienced higher non-adherence and increased
 discontinuati...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2662249</comments>
            <pubDate>Tue, 28 Jul 2009 18:28:56 +0100</pubDate>
            <guid isPermaLink="false">2662249</guid>        </item>
        <item>
            <title>The impact of missing data in the estimation of concentration index: a potential source of bias</title>
            <link>http://www.medworm.com/index.php?rid=2639417&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F1v0218q16717261m%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The purpose of this paper is to raise awareness of missing data when concentration indices are used to evaluate health-related
 inequality. Concentration indices are most commonly calculated using individual-level survey data. Incomplete data is a pervasive
 problem faced by most applied researchers who use survey data. The default analysis method in most statistical software packages
 is complete-case analysis. This excludes any cases where any variables are missing. If the missing variables in question are
 not completely random, the calculated concentration indices are likely to be biased, which may lead to inappropriate policy
 recommendations. In this paper, I use both a case study and a simulation study to show how complete-case analysis may lead
 to biases in the...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2639417</comments>
            <pubDate>Thu, 23 Jul 2009 09:10:31 +0100</pubDate>
            <guid isPermaLink="false">2639417</guid>        </item>
        <item>
            <title>Ten arguments for a societal perspective in the economic evaluation of medical innovations</title>
            <link>http://www.medworm.com/index.php?rid=2639418&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh81v50v034300857%2F</link>
            <description>Content Type Journal ArticleCategory EditorialDOI 10.1007/s10198-009-0173-2Authors
		Bengt Jönsson, Stockholm School of Economics Department of Economics Box 6501 113 83 Stockholm Sweden
	

	
		Journal The European Journal of Health EconomicsOnline ISSN 1618-7601Print ISSN 1618-7598 (Source: The European Journal of Health Economics)</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2639418</comments>
            <pubDate>Wed, 22 Jul 2009 01:53:16 +0100</pubDate>
            <guid isPermaLink="false">2639418</guid>        </item>
        <item>
            <title>Private expenditure and the role of private health insurance in Greece: status quo and future trends</title>
            <link>http://www.medworm.com/index.php?rid=2597284&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ffjg6361g51221113%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The health care system in Greece is financed in almost equal proportions by public and private sources. Private expenditure,
 consists mostly of out-of-pocket and under-the-table payments. Such payments strongly suggest dissatisfaction with the public
 system, due to under financing during the last 25&amp;nbsp;years. This gap has been filled rapidly by the private sector. From this
 point of view, one might suggest that the flourishing development of private provision may lead in turn to a corresponding
 growth in private health insurance (PHI). This paper aims to examine the role of PHI in Greece, to identify the factors influencing
 its development, and to make some suggestions about future policies and trends. In the decade of 1985–1995 PHI show increasing
 activity, r...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2597284</comments>
            <pubDate>Sat, 11 Jul 2009 06:47:46 +0100</pubDate>
            <guid isPermaLink="false">2597284</guid>        </item>
        <item>
            <title>Health insurance in Croatia: dynamics and politics of balancing revenues and expenditures</title>
            <link>http://www.medworm.com/index.php?rid=2597285&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F77p174j4078k860w%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Since 2002, the Croatian social health insurance system has undergone substantial reforms, initiated for the most part with
 the aim of addressing the perpetual financial deficits of the state health insurance fund. While the reforms focussed heavily
 on increasing the inflow of private funds into the health care system, underlying inefficiencies contributing significantly
 to poor financial performance have been largely ignored. Furthermore, contrary to demographic trends and developments in social
 health insurance schemes in other countries, funding health care became even more dependent on its main collection mechanism—payroll
 tax—and consequently on the employment ratio and wage level. Little effort has been made to diversify the revenue base or
 to increase t...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2597285</comments>
            <pubDate>Sat, 11 Jul 2009 06:47:45 +0100</pubDate>
            <guid isPermaLink="false">2597285</guid>        </item>
        <item>
            <title>BMI and Spanish labour status: evidence by gender from the city of Barcelona</title>
            <link>http://www.medworm.com/index.php?rid=2597286&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn0183l1476376ml4%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The purpose of this study was to analyse whether BMI has any consequence on being employed or not in a specific Spanish labour
 market (those living in the city of Barcelona). Self-reported data were corrected by means of specific conversion formulas.
 Additionally, participants were questioned about making use of an IV procedure (gap between individual BMI score and the average
 value of those either with the same attained educational level by gender, or living in the same district). Irrespective of
 the strategy applied, the results point to the presence of BMI effects on labour market status exclusively for women, specifically
 those up to 45&amp;nbsp;years old.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-009-0169-yAuthors
		Toni Mora, Univer...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2597286</comments>
            <pubDate>Sat, 11 Jul 2009 06:47:44 +0100</pubDate>
            <guid isPermaLink="false">2597286</guid>        </item>
        <item>
            <title>A review of studies mapping (or cross walking) non-preference based measures of health to generic preference-based measures</title>
            <link>http://www.medworm.com/index.php?rid=2592886&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ffg727601052478t2%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Clinical studies use a wide variety of health status measures to measure health related quality of life, many of which cannot
 be used in cost-effectiveness analysis using cost per quality adjusted life year (QALY). Mapping is one solution that is gaining
 popularity as it enables health state utility values to be predicted for use in cost per QALY analysis when no preference-based
 measure has been included in the study. This paper presents a systematic review of current practice in mapping between non-preference
 based measures and generic preference-based measures, addressing feasibility and validity, circumstances under which it should
 be considered and lessons for future mapping studies. This review found 30 studies reporting 119 different models. Performance
 of ...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2592886</comments>
            <pubDate>Thu, 09 Jul 2009 12:15:56 +0100</pubDate>
            <guid isPermaLink="false">2592886</guid>        </item>
        <item>
            <title>A social preference valuations set for EQ-5D health states in Flanders, Belgium</title>
            <link>http://www.medworm.com/index.php?rid=2590504&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F8j4g3751k3651174%2F</link>
            <description>This study aimed at deriving a preference valuation set for EQ-5D health states from the general Flemish public in Belgium.
 A EuroQol valuation instrument with 16 health states to be valued on a visual analogue scale was sent to a random sample of
 2,754 adults. The initial response rate was 35%. Eventually, 548 (20%) respondents provided useable valuations for modeling.
 Valuations for 245 health states were modeled using a random effects model. The selection of the model was based on two criteria:
 health state valuations must be consistent, and the difference with the directly observed valuations must be small. A model
 including a value decrement if any health dimension of the EQ-5D is on the worst level was selected to construct the social
 health state valuation set. A comparison wi...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2590504</comments>
            <pubDate>Tue, 07 Jul 2009 15:27:57 +0100</pubDate>
            <guid isPermaLink="false">2590504</guid>        </item>
        <item>
            <title>Hospital costs for treatment of acute heart failure: economic analysis of the REVIVE II study</title>
            <link>http://www.medworm.com/index.php?rid=2590505&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F01285671470ru2wx%2F</link>
            <description>Conclusions&amp;nbsp;&amp;nbsp;In the REVIVE II trial, patients treated with levo had shorter LOS and lower cost for the initial hospital admission relative
 to patients treated with SOC. Based on sub-group analysis of patients administered per the current label, levo appears cost-effective
 relative to SOC.
 
 
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-009-0165-2Authors
		Greg de Lissovoy, United BioSource Corporation 7101 Wisconsin Avenue, Suite 600 Bethesda MD 20814 USAKathy Fraeman, United BioSource Corporation 7101 Wisconsin Avenue, Suite 600 Bethesda MD 20814 USAJohn R. Teerlink, University of California Section of Cardiology, San Francisco Veterans Affairs Medical Center and School of Medicine San Francisco CA USAJohn Mullahy, University of Wisconsin Departmen...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2590505</comments>
            <pubDate>Tue, 07 Jul 2009 15:27:56 +0100</pubDate>
            <guid isPermaLink="false">2590505</guid>        </item>
        <item>
            <title>The added value of thorough economic evaluation of telemedicine networks</title>
            <link>http://www.medworm.com/index.php?rid=2559571&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv4180669p6163804%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;This paper proposes a thorough framework for the economic evaluation of telemedicine networks. A standard cost analysis methodology
 was used as the initial base, similar to the evaluation method currently being applied to telemedicine, and to which we suggest
 adding subsequent stages that enhance the scope and sophistication of the analytical methodology. We completed the methodology
 with a longitudinal and stakeholder analysis, followed by the calculation of a break-even threshold, a calculation of the
 economic outcome based on net present value (NPV), an estimate of the social gain through external effects, and an assessment
 of the probability of social benefits. In order to illustrate the advantages, constraints and limitations of the proposed
 framework, we tes...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2559571</comments>
            <pubDate>Mon, 29 Jun 2009 10:27:06 +0100</pubDate>
            <guid isPermaLink="false">2559571</guid>        </item>
        <item>
            <title>Primary care delivery, risk pooling and economic efficiency</title>
            <link>http://www.medworm.com/index.php?rid=2501037&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F327228t3n76h8755%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The consequences of consumer-driven health care under different health insurance plans are studied by means of a game theoretic
 approach. Suitable demand-side cost-sharing can induce consumer behavior that avoids over-treatment when there are information
 asymmetries between providers and consumers, leading to the efficient recommendations and provision of treatment by providers.
 If under-treatment can be penalized, then a full insurance model that pays providers a fixed salary and fee-for-service or
 one that requires patients to present a referral letter before specialist care is delivered also achieves provision efficiency.
 The two models, however, yield higher welfare for consumers. Hence, the findings in this paper favor some amount of regulation
 in health-care...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2501037</comments>
            <pubDate>Tue, 16 Jun 2009 05:50:33 +0100</pubDate>
            <guid isPermaLink="false">2501037</guid>        </item>
        <item>
            <title>Cost-effectiveness of pregabalin versus venlafaxine in the treatment of generalized anxiety disorder: findings from a Spanish perspective</title>
            <link>http://www.medworm.com/index.php?rid=2501038&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr76022340816q0mh%2F</link>
            <description>The objective of the present study was to describe a new model of the cost-effectiveness of treatment of generalized anxiety
 disorder (GAD) and its application to a comparison of pregabalin versus venlafaxine extended-release (XR) from a Spanish healthcare
 perspective. Microsimulation techniques, including Hamilton Anxiety Scale (HAM-A) score, number of weeks with minimal or no
 anxiety (HAM-A&amp;nbsp;≤&amp;nbsp;9), and quality-adjusted life-years (QALYs), were used to predict treatment outcomes for patients with moderate-to-severe
 GAD who would be treated with pregabalin vs venlafaxine XR. Expected levels of healthcare utilization and unit cost of care
 are derived from Spanish published sources. We express cost-effectiveness alternatively in terms of incremental cost per additional
 week w...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2501038</comments>
            <pubDate>Tue, 09 Jun 2009 12:53:23 +0100</pubDate>
            <guid isPermaLink="false">2501038</guid>        </item>
        <item>
            <title>Saving lives, money and resources: drug and CABG/PCI use after myocardial infarction in a Swedish record-linkage study</title>
            <link>http://www.medworm.com/index.php?rid=2462458&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F54h48303043g7346%2F</link>
            <description>Conclusion&amp;nbsp;&amp;nbsp;Costs for out-patient care accounted for 25% and drugs for 5% of total costs. If patients not treated with simvastatin or
 clopidogrel had received these drugs, an additional 154–306 lives might have been saved. Drug costs would be higher, but total
 costs lower. Thus, even expensive drugs may reduce overall costs.
 
 
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-009-0161-6Authors
		Lars Wilhelmsen, University of Gothenburg Gothenburg SwedenLennart Welin, Lidköping Hospital Lidköping SwedenAnders Odén, Chalmers University of Technology Göteborg SwedenArne Björnberg, Pollex Retro Research Stockholm Sweden
	

	
		Journal The European Journal of Health EconomicsOnline ISSN 1618-7601Print ISSN 1618-7598 (Source: The European Journal of H...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2462458</comments>
            <pubDate>Thu, 04 Jun 2009 09:49:54 +0100</pubDate>
            <guid isPermaLink="false">2462458</guid>        </item>
        <item>
            <title>The economics of cochlear implant management in France: a multicentre analysis</title>
            <link>http://www.medworm.com/index.php?rid=2445656&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ff313338447743306%2F</link>
            <description>This study assessed the direct medical cost of cochlear implantation in children and adults in France. A prospective multicentre
 study involving 19 French University Hospitals included 268 children and 201 adults who were severely to profoundly hearing-impaired.
 Medical resources utilisation included diagnostic tests, in-patient care, device implants, adverse events and follow-up visits
 for rehabilitation in the 1st&amp;nbsp;year. The mean costs were &amp;#8364;34,686 per child and &amp;#8364;31,946 per adult. The cost of device implant
 represents 64.4% and 68.8% of the total cost for children and adults, respectively. The current reform of financing of the
 healthcare system requires detailed knowledge of the costs of interventions, hence the costs of cochlear implantation should
 be factored int...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2445656</comments>
            <pubDate>Thu, 28 May 2009 09:19:48 +0100</pubDate>
            <guid isPermaLink="false">2445656</guid>        </item>
        <item>
            <title>Alcohol and labor supply: the case of Iceland</title>
            <link>http://www.medworm.com/index.php?rid=2435787&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv4n581g143366q22%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;At a time when the government of Iceland is considering privatization of alcohol sales and a reduction of its governmental
 fees, it is timely to estimate the potential effects of this policy change. Given that the privatization of sales coupled
 with a tax reduction should lead to a decrease in the unit price of alcohol, one would expect the quantity consumed to increase.
 While it is of interest to project the impact of the proposed bill on the market for alcohol, another important consideration
 is the impact that increased alcohol consumption and, more specifically, probable alcohol misuse would have on other markets
 in Iceland. The only available study on this subject using Icelandic data yields surprising results. Tómasson et al. (Scand
 J Public Health 32:47–...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2435787</comments>
            <pubDate>Sun, 24 May 2009 06:09:49 +0100</pubDate>
            <guid isPermaLink="false">2435787</guid>        </item>
        <item>
            <title>The relevance of unrelated costs internal and external to the healthcare sector to the outcome of a cost-comparison analysis of secondary prevention: the case of general colorectal cancer screening in the German population</title>
            <link>http://www.medworm.com/index.php?rid=2421896&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F8x5u7017176k8456%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The potential of secondary prevention measures, such as cancer screening, to produce cost savings in the healthcare sector
 is a controversial issue in healthcare economics. Potential savings are calculated by comparing treatment costs with the cost
 of a prevention program. When survivors’ subsequent unrelated health care costs are included in the calculation, however,
 the overall cost of disease prevention rises. What have not been studied to date are the secondary effects of fatal disease
 prevention measures on social security systems. From the perspective of a policy maker responsible for a social security system
 budget, it is not only future healthcare costs that are relevant for budgeting, but also changes in the contributions to,
 and expenditures from, stat...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2421896</comments>
            <pubDate>Sun, 17 May 2009 06:53:54 +0100</pubDate>
            <guid isPermaLink="false">2421896</guid>        </item>
        <item>
            <title>Interactions between cigarette and alcohol consumption in rural China</title>
            <link>http://www.medworm.com/index.php?rid=2421897&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy411133484600046%2F</link>
            <description>The objective of this paper is to analyze interdependencies between cigarette and alcohol consumption in rural China, using
 panel data for 10&amp;nbsp;years (1994–2003) for rural areas of 26 Chinese provinces. There have been many studies in which cigarette
 and alcohol consumption have been considered separately but few to date for China on interactions between the consumption
 of these two products. Taxes are often recommended as a tool to reduce alcohol and cigarette consumption. If cigarettes and
 alcohol are complements, taxing one will reduce the consumption of both and thus achieve a double public health dividend.
 However, if they are substitutes, taxing one will induce consumers to increase consumption of the other, offsetting the public
 health benefits of the tax. Our results ind...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2421897</comments>
            <pubDate>Sun, 17 May 2009 06:53:53 +0100</pubDate>
            <guid isPermaLink="false">2421897</guid>        </item>
        <item>
            <title>Inpatient length of stay: a finite mixture modeling analysis</title>
            <link>http://www.medworm.com/index.php?rid=2411806&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F280366456301g168%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Length of stay (LOS) in hospital for inpatient treatment is a measure of crucial recovery time. Using nationwide data on inpatient
 healthcare in India, a three-component finite mixture negative binomial model was found to provide a reasonable fit to the
 heterogeneous LOS distribution. Associated risk factors for short-stay, medium-stay and long-stay subgroups were identified
 from the respective negative binomial components. In addition, significant heterogeneities within each group were also found.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-009-0153-6Authors
		Chungkham Holendro Singh, North-Eastern Hill University Department of Statistics Umshing, Mawkynroh Shillong 793022 Meghalaya IndiaLaishram Ladusingh, International Institute for P...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2411806</comments>
            <pubDate>Mon, 11 May 2009 05:32:22 +0100</pubDate>
            <guid isPermaLink="false">2411806</guid>        </item>
        <item>
            <title>Total or partial knee replacement? Cost-utility analysis in patients with knee osteoarthritis based on a 2-year observational study</title>
            <link>http://www.medworm.com/index.php?rid=2411808&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh057710656789jw3%2F</link>
            <description>The objective of this study was to evaluate incremental cost-utility of total knee replacement (TKR) versus unicompartmental
 knee arthroplasty (UKA) in patients with knee osteoarthritis (OA) of the medial compartment. A 2-year non-randomised prospective
 observational cohort study was conducted in unicompartmental knee osteoarthritis patients scheduled for TKR (n&amp;nbsp;=&amp;nbsp;431) or UKA (n&amp;nbsp;=&amp;nbsp;102). Costs were identified using administrative databases and health outcomes were measured using the SF-36 and the Oxford
 knee score (OKS) 1&amp;nbsp;week before, 6&amp;nbsp;months after, and 2&amp;nbsp;years after surgery. The incremental cost-utility ratio (ICUR) for TKR
 versus UKA was calculated and its 95% confidence interval estimated using a nonparametric bootstrapping technique. Cost-effectiv...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2411808</comments>
            <pubDate>Sun, 10 May 2009 05:44:57 +0100</pubDate>
            <guid isPermaLink="false">2411808</guid>        </item>
        <item>
            <title>In which ways do unhealthy people older than 50 exit the labour market in France?</title>
            <link>http://www.medworm.com/index.php?rid=2411807&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fr0x5q7wv452430t3%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Among 55–64&amp;nbsp;year olds, poor health is a reason for leaving the labour market early within the framework of schemes such as
 not only Early Retirement for Certain Employees (or Early Retirement for Asbestos Workers), but also by absence from the workforce
 (sick pay and disability pensions, respectively). It is interesting to single out the controlling factors for participation
 in or absence from the labour market after 50 and the link between poor health and employment status. The prevalence of functional
 limitations in everyday activities leads to a more pronounced exclusion of those over 50 years old from the labour market.
 Some of those aged between 55 and 59 on disability benefits become unemployed and do not look for work; in other words, they
 are potent...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2411807</comments>
            <pubDate>Sun, 10 May 2009 05:44:57 +0100</pubDate>
            <guid isPermaLink="false">2411807</guid>        </item>
        <item>
            <title>Contractual design and PPPs for hospitals: lessons for the Portuguese model</title>
            <link>http://www.medworm.com/index.php?rid=2338534&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv6314525106w4075%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Recently the Portuguese Government announced the launching of public–private partnerships (PPPs) to build hospitals with the
 distinctive feature that infrastructure construction and clinical activities management will be awarded to separate private
 parties. Also, one of the parties will be in charge of providing soft facilities. We explore alternative configurations of
 contracts and assess whether the equilibrium allocations attain the first-best solution.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-009-0152-7Authors
		Pedro Pita Barros, Universidade Nova de Lisboa Faculdade de Economia Campus de Campolide 1099-032 Lisboa PortugalXavier Martinez-Giralt, Universitat Autònoma de Barcelona CODE and Departament d’Economia Edifici B 08193...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2338534</comments>
            <pubDate>Thu, 09 Apr 2009 09:36:50 +0100</pubDate>
            <guid isPermaLink="false">2338534</guid>        </item>
        <item>
            <title>The lack of theoretical support for using person trade-offs in QALY-type models</title>
            <link>http://www.medworm.com/index.php?rid=2321124&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fj480520231265v1n%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Considerable support for the use of person trade-off methods to assess the quality-adjustment factor in quality-adjusted life
 years (QALY) models has been expressed in the literature. The WHO has occasionally used similar methods to assess the disability
 weights for calculation of disability-adjusted life years (DALYs). This paper discusses the theoretical support for the use
 of person trade-offs in QALY-type measurement of (changes in) population health. It argues that measures of this type based
 on such quality-adjustment factors almost always violate the Pareto principle, and so lack normative justification.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-009-0150-9Authors
		Lars Peter Østerdal, University of Copenhagen Department of Eco...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2321124</comments>
            <pubDate>Thu, 02 Apr 2009 05:52:06 +0100</pubDate>
            <guid isPermaLink="false">2321124</guid>        </item>
        <item>
            <title>Total costs of injury from accidents in the home and during education, sports and leisure activities: estimates for Norway with assessment of uncertainty</title>
            <link>http://www.medworm.com/index.php?rid=2294156&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw5552lp32031m847%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Injury accidents occurring in the home, during educational, sports or leisure activities were estimated from samples of hospital
 data, combined with fatality data from vital statistics. Uncertainty of estimated figures was assessed in simulation-based
 analysis. Total economic costs to society from injuries and fatalities due to such accidents were estimated at approximately
 NOK 150&amp;nbsp;billion per year. The estimated costs reveal the scale of the public health problem and lead to arguments for the
 establishment of a proper injury register for the identification of preventive measures to reduce the costs to society.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-009-0149-2Authors
		Knut Veisten, Institute of Transport Economics Gaustadallee...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2294156</comments>
            <pubDate>Wed, 25 Mar 2009 06:50:03 +0100</pubDate>
            <guid isPermaLink="false">2294156</guid>        </item>
        <item>
            <title>Cost-effectiveness of immunosuppressive regimens in renal transplant recipients in Germany: a model approach</title>
            <link>http://www.medworm.com/index.php?rid=2281680&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F10h433345887jq8k%2F</link>
            <description>Conclusions&amp;nbsp;&amp;nbsp;Over both the 2-year and the 10-year time horizon, sirolimus-based immunosuppression represents a cost-effective option in
 renal transplantation in Germany.
 
 
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-009-0148-3Authors
		Jan Steffen Jürgensen, Charité-Universitaetsmedizin Berlin Department of Nephrology and Medical Intensive Care Campus Virchow Klinikum, Augustenburger Platz 1 13353 Berlin GermanyWolfgang Arns, Kliniken der Stadt Köln GmbH Cologne GermanyBastian Haß, IMS HEALTH GmbH &amp; Co. OHG Health Economics and Outcomes Research Nuremberg Germany
	

	
		Journal The European Journal of Health EconomicsOnline ISSN 1618-7601Print ISSN 1618-7598 (Source: The European Journal of Health Economics)</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2281680</comments>
            <pubDate>Fri, 20 Mar 2009 09:53:52 +0100</pubDate>
            <guid isPermaLink="false">2281680</guid>        </item>
        <item>
            <title>Procedures and methods of benefit assessments for medicines in Germany: give the child a name</title>
            <link>http://www.medworm.com/index.php?rid=2281682&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F560840136141649r%2F</link>
            <description>Content Type Journal ArticleCategory CommentaryDOI 10.1007/s10198-009-0147-4Authors
		Holger Schünemann, McMaster University Health Sciences Centre Department of Clinical Epidemiology and Biostatistics Room 2C10B, 1200 Main Street West Hamilton ON L8N 3Z5 CanadaRegina Kunz, McMaster University Health Sciences Centre Department of Clinical Epidemiology and Biostatistics Room 2C10B, 1200 Main Street West Hamilton ON L8N 3Z5 CanadaYngve Falck-Ytter, McMaster University Health Sciences Centre Department of Clinical Epidemiology and Biostatistics Room 2C10B, 1200 Main Street West Hamilton ON L8N 3Z5 CanadaNancy Santesso, McMaster University Health Sciences Centre Department of Clinical Epidemiology and Biostatistics Room 2C10B, 1200 Main Street West Hamilton ON L8N 3Z5 Canada
	

	
		Journal ...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2281682</comments>
            <pubDate>Tue, 17 Mar 2009 07:05:44 +0100</pubDate>
            <guid isPermaLink="false">2281682</guid>        </item>
        <item>
            <title>Perceived job security and sickness absence: a study on moral hazard</title>
            <link>http://www.medworm.com/index.php?rid=2267282&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx07550g7n5ux8460%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;A moral hazard problem was investigated by analysing the individual behaviour of female and male employees with regard to
 utilisation of sickness insurance in connection with perceived job security. It was hypothesised that employees with a higher
 perceived job security take more frequent sickness absence. Perceived higher job security is indicated by three variables,
 namely a permanent job contract, no unemployment history, and native ethnicity. The effect of perceived job security is expected
 to be stronger on short-term than on long-term sickness absence, since a medical certificate is required for the latter. Public
 health survey data from Stockholm County, Sweden, covering the year 2002 was used. Using logistic regression analyses separately
 for short- and lo...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2267282</comments>
            <pubDate>Fri, 13 Mar 2009 10:13:16 +0100</pubDate>
            <guid isPermaLink="false">2267282</guid>        </item>
        <item>
            <title>Estimating the cost related to surveillance of colorectal cancer in a French population</title>
            <link>http://www.medworm.com/index.php?rid=2239076&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg2q83t33765tw041%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Little is known about costs related to the surveillance of patients that have undergone curative resection of colorectal cancer.
 The aim of this study was to calculate the observed surveillance costs for 385 patients followed-up over a 3-year period,
 to estimate surveillance costs if French guidelines are respected, and to identify the determinants related to surveillance
 costs to derive a global estimation for France, using a linear mixed model. The observed mean surveillance cost was &amp;#8364;&amp;nbsp;713.
 If French recommendations were strictly applied, the estimated mean cost would vary between &amp;#8364;&amp;nbsp;680 and &amp;#8364;&amp;nbsp;1,069 according to
 the frequency of abdominal ultrasound. The predicted determinants of cost were: age, recurrence, duration of surveillance...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2239076</comments>
            <pubDate>Wed, 04 Mar 2009 16:22:04 +0100</pubDate>
            <guid isPermaLink="false">2239076</guid>        </item>
        <item>
            <title>On the welfare theoretic foundation of cost-effectiveness analysis—the case when survival is not affected</title>
            <link>http://www.medworm.com/index.php?rid=2239077&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw3157308n53m0246%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;This paper develops a welfare theoretic foundation for cost-effectiveness analysis (CEA) when survival is not affected. With
 this foundation, all costs and their corresponding utility-terms should be included. A key question, though, is whether these
 utility-terms are consistent with quality-adjusted life year (QALY) (utility) theory or not. The results show that health
 care costs and changes in the utility of health should be included. However, as QALYs do not capture the utility of changes
 in consumption (as this utility must be independent of health, according to QALY theory), the corresponding changes in consumption
 costs should be excluded. Regarding the costs for changes in absence from work, these should only be included if the utility
 of changes in the amo...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2239077</comments>
            <pubDate>Tue, 03 Mar 2009 10:59:44 +0100</pubDate>
            <guid isPermaLink="false">2239077</guid>        </item>
        <item>
            <title>Why the econometrician is in good spirits: a workshop through the looking glass</title>
            <link>http://www.medworm.com/index.php?rid=2186796&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ffm6173782705612q%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;
 Vita brevis, ars longa (or...life is too short for abstracts).
 
	Content Type Journal ArticleCategory EditorialDOI 10.1007/s10198-009-0143-8Authors
		Carl Hampus Lyttkens, Lund University Department of Economics P.O. Box 7082 220 07 Lund Sweden
	

	
		Journal The European Journal of Health EconomicsOnline ISSN 1618-7601Print ISSN 1618-7598 (Source: The European Journal of Health Economics)</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2186796</comments>
            <pubDate>Fri, 13 Feb 2009 08:12:10 +0100</pubDate>
            <guid isPermaLink="false">2186796</guid>        </item>
        <item>
            <title>Response to the expertise: Procedures and methods of benefit assessments for medicines in Germany, by Geertruida E. Bekkering and Jos Kleijnen</title>
            <link>http://www.medworm.com/index.php?rid=2086493&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F75207j82472541nx%2F</link>
            <description>Content Type Journal ArticleCategory CommentaryDOI 10.1007/s10198-008-0142-1Authors
		Klaus Koch, Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), Institute for Quality and Efficiency in Health Care Dillenburger Straße 27 51105 Cologne GermanyStefan Lange, Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG), Institute for Quality and Efficiency in Health Care Dillenburger Straße 27 51105 Cologne Germany
	

	
		Journal The European Journal of Health EconomicsOnline ISSN 1618-7601Print ISSN 1618-7598 (Source: The European Journal of Health Economics)</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2086493</comments>
            <pubDate>Sat, 03 Jan 2009 06:52:50 +0100</pubDate>
            <guid isPermaLink="false">2086493</guid>        </item>
        <item>
            <title>Is there a “continental” view of health economics evaluation?</title>
            <link>http://www.medworm.com/index.php?rid=2072882&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F532154p6331k8323%2F</link>
            <description>Content Type Journal ArticleCategory EditorialDOI 10.1007/s10198-008-0141-2Authors
		Claude Le Pen, University of Paris-Dauphine 75016 Paris France
	

	
		Journal The European Journal of Health EconomicsOnline ISSN 1618-7601Print ISSN 1618-7598 (Source: The European Journal of Health Economics)</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2072882</comments>
            <pubDate>Thu, 01 Jan 2009 06:51:40 +0100</pubDate>
            <guid isPermaLink="false">2072882</guid>        </item>
        <item>
            <title>Cost-effectiveness of strong opioids focussing on the long-term effects of opioid-related fractures: a model approach</title>
            <link>http://www.medworm.com/index.php?rid=2059594&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb4x52x0655607611%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Opioid analgesics are known to impact on the central nervous system (CNS). These CNS side effects, such as dizziness and confusion,
 have been shown to lead to an increased risk of falling with subsequent fractures in elderly patients being treated with opioids.
 The risk of experiencing fractures has been shown to be dependent on the substance administered. Therefore, a health economic
 model was developed to investigate the cost-effectiveness of the most commonly used strong opiods in Germany, focussing on
 opioid-related fractures. By means of a Markov model, the consequences of hip, spine and forearm fractures due to the prior
 administration of transdermal (TD) buprenorphine, TD fentanyl, oral oxycodone as well as oral morphine were assessed from
 the perspectives ...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2059594</comments>
            <pubDate>Sun, 21 Dec 2008 08:21:02 +0100</pubDate>
            <guid isPermaLink="false">2059594</guid>        </item>
        <item>
            <title>GPs as citizens’ agents: prescription behavior and altruism</title>
            <link>http://www.medworm.com/index.php?rid=2039110&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb1718672574kk664%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;To curb the heavily increasing drug budgets some Danish counties have introduced voluntary agreements between general practitioners
 (GPs) and health authorities. We extend the models of generic prescription by Hellerstein (Rand J Econ 29(1):108–136, 1998)
 and Lundin (J Health Econ 19:639–662, 2000) to allow for substitution between analogues and use difference-in-difference models
 to assess the effect on two drug groups (lipid-lowering and rheumatism drugs). For both drug groups we find evidence of a
 significant effect of the intervention. In the case of lipid-lowering drugs, we found a significant larger impact on GPs with
 low loyalty to the insurer and with indication of low prescription quality. In contrast we found that the intervention had
 a significantly...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2039110</comments>
            <pubDate>Sun, 14 Dec 2008 09:16:17 +0100</pubDate>
            <guid isPermaLink="false">2039110</guid>        </item>
        <item>
            <title>Importance of sociodemographic and morbidity aspects in measuring health-related quality of life: performances of three tools</title>
            <link>http://www.medworm.com/index.php?rid=2032431&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn5876121t516wg80%2F</link>
            <description>Conclusions&amp;nbsp;&amp;nbsp;Overall, the agreement between questionnaires scores was quite low, whilst the correlation level was good. Questionnaire scores
 were influenced by socio-demographic and clinical variables in a similar way, especially SF6D and EQ5D. Therefore, the descriptive
 capacity of SF6D and EQ5D was found to be similar.
 
 
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-008-0139-9Authors
		Cecilia Quercioli, University of Siena Department of Public Health Via Aldo Moro 53100 Siena ItalyGabriele Messina, University of Siena Department of Public Health Via Aldo Moro 53100 Siena ItalyEmanuela Barbini, University of Siena Department of Public Health Via Aldo Moro 53100 Siena ItalyGiovanni Carriero, General Practice, Local Health Authority 7 Siena ItalyMar...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2032431</comments>
            <pubDate>Wed, 10 Dec 2008 07:56:48 +0100</pubDate>
            <guid isPermaLink="false">2032431</guid>        </item>
        <item>
            <title>Can Mediterranean diet 
 really
 influence obesity? Evidence from propensity score matching</title>
            <link>http://www.medworm.com/index.php?rid=2016381&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F147v088717qg8884%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Worldwide obesity rates have stimulated interest in healthy dietary patterns. One well-known dietary pattern is the Mediterranean
 diet, which has been linked with several beneficial health effects. However, concerns have also been raised regarding the
 Mediterranean diet’s role in promoting weight gain. We explored the effect of the Mediterranean diet on body mass index using
 the propensity score matching approach. We found no statistically significant average treatment effect on the treated and
 therefore cannot confirm that a causal link exists between Mediterranean diet and body mass index.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-008-0138-xAuthors
		Andreas C. Drichoutis, Agricultural University of Athens Laboratory of Political E...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=2016381</comments>
            <pubDate>Fri, 05 Dec 2008 09:18:34 +0100</pubDate>
            <guid isPermaLink="false">2016381</guid>        </item>
        <item>
            <title>Modelling health expenditure at the household level in Greece</title>
            <link>http://www.medworm.com/index.php?rid=1995678&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fy273205058277242%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Health expenditure data are known to be afflicted by restricted range, zero values, skewness and kurtosis. Several methods
 for modelling such data have been suggested in the literature to cope with these problems. This paper compares the performance
 of several alternative estimators, including two-part models and generalised linear models. The dependent variable is household
 expenditure on health care in Greece, a country where out-of-pocket health expenditure is higher than anywhere else in the
 European Union, whether as a proportion of GDP, as a share of all health spending, or in per capita terms. To facilitate comparison
 of model performance, household health expenditure is examined in two different specifications: expenditure on all health
 care (where zero va...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1995678</comments>
            <pubDate>Thu, 27 Nov 2008 09:21:09 +0100</pubDate>
            <guid isPermaLink="false">1995678</guid>        </item>
        <item>
            <title>The socioeconomic costs of mental illness in Spain</title>
            <link>http://www.medworm.com/index.php?rid=1989477&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb079324675853823%2F</link>
            <description>In conclusion, the costs of mental illness in Spain make a considerable economic
 impact from a societal perspective.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-008-0135-0Authors
		Juan Oliva-Moreno, Universidad de Castilla la Mancha and FEDEA Facultad de Ciencias Jurídicas y Sociales de Toledo, Análisis Económico y Finanzas Cobertizo de San Pedro Mártir s/n 45071 Toledo SpainJulio López-Bastida, Evaluation and Planning Services, Canary Island Health Services Canary Islands SpainAngel Luis Montejo-González, Universidad de Salamanca Hospital Universitario de Salamanca, Faculty of Medicine Salamanca SpainRubén Osuna-Guerrero, Universidad Nacional de Educación a Distancia (UNED) Madrid SpainBeatriz Duque-González, Evaluation and Planning Services, Canary...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1989477</comments>
            <pubDate>Tue, 25 Nov 2008 06:48:56 +0100</pubDate>
            <guid isPermaLink="false">1989477</guid>        </item>
        <item>
            <title>Material versus social deprivation and health: a case study of an urban area</title>
            <link>http://www.medworm.com/index.php?rid=1974313&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn36j2787xg073248%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Socioeconomic factors are one of the main determinants of health inequalities. However, which component of socioeconomic status
 affects health most and how that relationship should be measured remains an open question. The aim of this study was to compare
 material and social deprivation indexes in order to determine which better explains health inequalities within an urban area.
 Following a review of the literature on small area deprivation indexes, a case study of the Italian city Genoa is presented.
 The city of Genoa is split into 71 small areas [urbanistic units (UU)], each of which has about 9,500 inhabitants. For each
 small area, socioeconomic indicators were extracted from the 2001 Census, whereas health indicators were computed from the
 death registry for 2...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1974313</comments>
            <pubDate>Wed, 19 Nov 2008 08:01:48 +0100</pubDate>
            <guid isPermaLink="false">1974313</guid>        </item>
        <item>
            <title>The cost of resistance: incremental cost of methicillin-resistant 
 Staphylococcus aureus
 (MRSA) in German hospitals</title>
            <link>http://www.medworm.com/index.php?rid=1974314&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh8412713620k5254%2F</link>
            <description>We present a retrospective
 matched-pairs analysis of mortality, length of stay, and cost of MRSA patients based mainly on routine administrative data
 from 11 German hospitals. Our results show that MRSA patients stay in hospital 11&amp;nbsp;days longer, exhibit 7% higher mortality,
 are 7% more likely to undergo mechanical ventilation, and cause significantly higher total costs (&amp;#8364;&amp;nbsp;8,198).
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-008-0132-3Authors
		Ansgar Resch, Im Nonnengarten 49 67098 Bad Dürkheim GermanyMichael Wilke, Dr. Wilke GmbH Werner-Eckert-Str. 12 81829 Munich GermanyChristian Fink, Rambøll Management GmbH Saarbrücker Straße 20/21 10405 Berlin Germany
	

	
		Journal The European Journal of Health EconomicsOnline ISSN 1618-7601Print ISS...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1974314</comments>
            <pubDate>Tue, 18 Nov 2008 08:01:12 +0100</pubDate>
            <guid isPermaLink="false">1974314</guid>        </item>
        <item>
            <title>Hybrid risk adjustment for pharmaceutical benefits</title>
            <link>http://www.medworm.com/index.php?rid=1967937&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh7374173567g2874%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;This paper analyses the application of hybrid risk adjustment versus either prospective or concurrent risk adjustment formulae
 in the context of funding pharmaceutical benefits for the population of an integrated healthcare delivery organisation in
 Catalonia during years 2002 and 2003. We apply a mixed formula and find that, compared to prospective only models, a hybrid
 risk adjustment model increases incentives for efficiency in the provision for low risk individuals in health organisations,
 not only as a whole but also within each internal department, by reducing within-group variation of drug expenditures.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-008-0133-2Authors
		Manuel García-Goñi, Universidad Complutense de Madrid Departamen...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1967937</comments>
            <pubDate>Sun, 16 Nov 2008 11:32:55 +0100</pubDate>
            <guid isPermaLink="false">1967937</guid>        </item>
        <item>
            <title>The economic costs of Group B Streptococcus (GBS) disease: prospective cohort study of infants with GBS disease in England</title>
            <link>http://www.medworm.com/index.php?rid=1954799&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F585040j9u716453v%2F</link>
            <description>This study shows that the health and social care costs for infants with GBS disease is, on average, two-fold higher
 during the first 2&amp;nbsp;years of life than for infants without GBS disease. These data should be used to inform policy decisions
 regarding the cost-effectiveness of prevention and treatment strategies for GBS disease during early childhood.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-008-0131-4Authors
		Elizabeth-Ann Schroeder, University of Oxford National Perinatal Epidemiology Unit Old Road Campus, Old Road, Headington Oxford OX3 7LF UKStavros Petrou, University of Oxford National Perinatal Epidemiology Unit Old Road Campus, Old Road, Headington Oxford OX3 7LF UKGail Balfour, St George’s, University of London Division of Child Health Cranme...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1954799</comments>
            <pubDate>Tue, 11 Nov 2008 07:56:44 +0100</pubDate>
            <guid isPermaLink="false">1954799</guid>        </item>
        <item>
            <title>Procedures and methods of benefit assessments for medicines in Germany</title>
            <link>http://www.medworm.com/index.php?rid=1944819&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F217585635q3j3921%2F</link>
            <description>In this report, ‘the institute’ is used when the text refers to any of these
 institutes.
 
 
 
 The legal framework for benefit assessments is laid out in the German Social Code Book version V (http://www.sozialgesetzbuch.de), Sects. 35b (§ 1), 139a (§ 4–6) and Sect. 139b (§ 3). It is specified that:
 
 
 
 •&amp;nbsp;
 
 The institute must guarantee high transparency.
 
 
 •&amp;nbsp;
 
 The institute must provide appropriate participation of relevant parties for the commission-related development of assessments,
 and opportunity for comment on all important segments of the assessment procedure.
 
 
 
 •&amp;nbsp;
 
 The institute has to report on the progress and results of the work at regular intervals.
 
 
 •&amp;nbsp;
 
 The institute is held to giving the commission to external exp...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1944819</comments>
            <pubDate>Thu, 06 Nov 2008 07:04:50 +0100</pubDate>
            <guid isPermaLink="false">1944819</guid>        </item>
        <item>
            <title>Biostatistical aspects for the use of evidence based medicine in health technology assessment</title>
            <link>http://www.medworm.com/index.php?rid=1944821&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F984765515972u4jk%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Health systems throughout the world are increasingly concerned with the evaluation of the effectiveness and cost-effectiveness
 of pharmaceuticals (and health technologies more generally), in order to enhance the extent to which scarce health resources
 are used efficiently. Regulatory processes designed to demonstrate efficacy, quality and safety are added to the concept of
 efficiency or value for money. These regulatory processes serve to identify and ensure that a product does indeed have a therapeutic
 effect; that it is manufactured to acceptable standards; and that it does not bring undue hazard to patients with use. A subsequent
 appraisal process considers if and where society might rationally bring the intervention into usage. It may be efficient for
 a health...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1944821</comments>
            <pubDate>Thu, 06 Nov 2008 07:04:49 +0100</pubDate>
            <guid isPermaLink="false">1944821</guid>        </item>
        <item>
            <title>Evidence-based benefit assessment of pharmaceuticals as a basis for rational and economical pharmaceutical therapy</title>
            <link>http://www.medworm.com/index.php?rid=1944820&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fh24440v7v16j727g%2F</link>
            <description>Content Type Journal ArticleCategory EditorialDOI 10.1007/s10198-008-0130-5Authors
		Thomas Müller, Federal Joint Committee (Gemeinsamer Bundesausschuss) Pharmaceuticals Department Siegburg Germany
	

	
		Journal The European Journal of Health EconomicsOnline ISSN 1618-7601Print ISSN 1618-7598
	
		Journal Volume Volume 9
	
		Journal Issue Volume 9, Supplement 1 / November, 2008 (Source: The European Journal of Health Economics)</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1944820</comments>
            <pubDate>Thu, 06 Nov 2008 07:04:49 +0100</pubDate>
            <guid isPermaLink="false">1944820</guid>        </item>
        <item>
            <title>Can we afford to ignore missing data in cost-effectiveness analyses?</title>
            <link>http://www.medworm.com/index.php?rid=1900391&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F163l371114354642%2F</link>
            <description>Content Type Journal ArticleCategory EditorialDOI 10.1007/s10198-008-0129-yAuthors
		Andrea Marshall, University of Warwick, Coventry Warwick Clinical Trials Unit Gibbet Hill Road Coventry CV4 7AL UKLucinda J. Billingham, University of Birmingham Cancer Research UK Clinical Trials Unit Birmingham UKStirling Bryan, University of Birmingham Health Economics Facility Birmingham UK
	

	
		Journal The European Journal of Health EconomicsOnline ISSN 1618-7601Print ISSN 1618-7598 (Source: The European Journal of Health Economics)</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1900391</comments>
            <pubDate>Tue, 21 Oct 2008 06:13:04 +0100</pubDate>
            <guid isPermaLink="false">1900391</guid>        </item>
        <item>
            <title>Factors affecting chronic obstructive pulmonary disease (COPD)-related costs: a multivariate analysis of a Swedish COPD cohort</title>
            <link>http://www.medworm.com/index.php?rid=1879326&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe743716771143p7q%2F</link>
            <description>The objective
 of this study was to identify factors affecting COPD-related costs. A cohort of 179 subjects with COPD was interviewed over
 the telephone on four occasions about their annual use of COPD-related resources. The data set and explanatory variables were
 analysed by means of multivariate regression techniques for six different types of cost: societal (or total), direct (health
 care) and indirect (productivity), and three subcomponents of direct costs—hospitalisation, outpatient and medication. Poor
 lung function, dyspnoea and asthma were independently associated with higher costs. Poor lung function (severity of COPD)
 significantly increased all six examined cost types. Dyspnoea (breathing problems) also increased costs, though to a varying
 extent. The presence of reporte...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1879326</comments>
            <pubDate>Tue, 14 Oct 2008 11:24:47 +0100</pubDate>
            <guid isPermaLink="false">1879326</guid>        </item>
        <item>
            <title>Cost-effectiveness of intensive atorvastatin therapy in secondary cardiovascular prevention in the United Kingdom, Spain, and Germany, based on the Treating to New Targets study</title>
            <link>http://www.medworm.com/index.php?rid=1810997&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fqn24g51j14171046%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The Treating to New Targets (TNT) clinical trial found that intensive 80&amp;nbsp;mg atorvastatin (A80) treatment reduced cardiovascular
 events by 22% when compared to 10&amp;nbsp;mg atorvastatin (A10) treatment. We evaluated the cost-effectiveness of intensive A80 vs
 A10 treatment in the United Kingdom (UK), Spain, and Germany. A lifetime Markov model was developed to predict cardiovascular
 disease-related events, costs, survival, and quality-adjusted life-years (QALYs). Treatment-specific event probabilities were
 estimated from the TNT clinical trial. Post-event survival, health-related quality of life, and country-specific medical-care
 costs were estimated using published sources. Intensive treatment with A80 increased both the per-patient QALYs and corresponding
 costs...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1810997</comments>
            <pubDate>Thu, 18 Sep 2008 06:37:53 +0100</pubDate>
            <guid isPermaLink="false">1810997</guid>        </item>
        <item>
            <title>Cost of skin cancer in England</title>
            <link>http://www.medworm.com/index.php?rid=1793829&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fxx12286w5667w28r%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;This paper estimates the financial cost of skin cancer in England. National Health Service (NHS) costs were calculated by
 combining published data on health service use by patients with skin cancer with published data on the unit cost of services.
 Indirect costs arising from individuals’ inability to function in their usual role as a result of skin cancer were estimated
 from incapacity benefit claims and numbers of registered deaths due to skin cancer. The total costs of skin cancer were around
 £240 million. Costs to the NHS represented 42% of the total.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-008-0127-0Authors
		S. Morris, Health Economics Research Group Brunel University LondonB. Cox, Imperial College Tanaka Business School, Sou...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1793829</comments>
            <pubDate>Sat, 13 Sep 2008 08:11:01 +0100</pubDate>
            <guid isPermaLink="false">1793829</guid>        </item>
        <item>
            <title>Exploring spatial patterns in general practice expenditure</title>
            <link>http://www.medworm.com/index.php?rid=1785569&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fa83l0l2689j64106%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The determinants for per capita general practitioner (GP) public expenditure across Danish municipalities are analysed using
 data from the period 1997–2004. Heterogeneity and dependency across years are controlled for. Spatial spillover effects across
 municipalities are investigated in order to disclose the spatial dynamics of public GP expenditure. The results reveal substantial
 heterogeneity and dependency across time, as well as the presence of a significant spatial spillover effect. The effects of
 determinants are seriously over-estimated if such features are ignored. The spatial coefficient is strongly significant and
 suggests that there is an indirect effect on expenditure of non-observable variables that are geographically concentrated.
 
	Content Type Jou...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1785569</comments>
            <pubDate>Wed, 10 Sep 2008 08:32:42 +0100</pubDate>
            <guid isPermaLink="false">1785569</guid>        </item>
        <item>
            <title>Factors affecting nurses’ decision to get the flu vaccine</title>
            <link>http://www.medworm.com/index.php?rid=1785568&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Ft0p8t557427r3960%2F</link>
            <description>The objective of this study was to identify factors that influence the decision whether or not to get the influenza (flu)
 vaccine among nurses in Israel by using the health belief model (HBM). A questionnaire distributed among 299 nurses in Israel
 in winter 2005/2006 included (1) socio-demographic information; (2) variables based on the HBM, including susceptibility,
 seriousness, benefits, barriers and cues to action; and (3) knowledge about influenza and the vaccine, and health motivation.
 A probit model was used to analyze the data. In Israel, the significant HBM categories affecting nurses’ decision to get a
 flu shot are the perceived benefits from vaccination and cues to action. In addition, nurses who are vaccinated have higher
 levels of (1) knowledge regarding the vaccine and...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1785568</comments>
            <pubDate>Wed, 10 Sep 2008 08:32:42 +0100</pubDate>
            <guid isPermaLink="false">1785568</guid>        </item>
        <item>
            <title>Quality choice in a health care market: a mixed duopoly approach</title>
            <link>http://www.medworm.com/index.php?rid=1722926&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn525871x13432m76%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;We investigate a health care market with uncertainty in a mixed duopoly, where a partially privatized public hospital competes
 against a private hospital in terms of quality choice. We use a simple Hotelling-type spatial competition model by incorporating
 mean–variance analysis and the framework of partial privatization. We show how the variance in the quality perceived by patients
 affects the true quality of medical care provided by hospitals. In addition, we show that a case exists in which the quality
 of the partially privatized hospital becomes higher than that of the private hospital when the patient’s preference for quality
 is relatively high.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-008-0120-7Authors
		Yasuo Sanjo, Nagoya ...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1722926</comments>
            <pubDate>Tue, 19 Aug 2008 21:03:21 +0100</pubDate>
            <guid isPermaLink="false">1722926</guid>        </item>
        <item>
            <title>Activity-based funding for National Health Service hospitals in England: managers’ experience and expectations</title>
            <link>http://www.medworm.com/index.php?rid=1685744&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu035721hq56ng743%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;Activity-based funding of hospital services has been introduced progressively since 2003 in the National Health Service (NHS)
 in England, under the name ‘Payment by Results’ (PbR). It represents a major change from previous funding arrangements based
 on annual “block” payments for large bundles of services. We interviewed senior local NHS managers about their experience
 and expectations of the impact of PbR. A high degree of ‘NHS solidarity’ was apparent, and competition between NHS hospitals
 was muted. PbR has been introduced against a background of numerous other efficiency incentives, and managers did not detect
 a further PbR-specific boost to efficiency. No impact on care quality, either positive or negative, is yet evident.
 
	Content Type Journal ...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1685744</comments>
            <pubDate>Tue, 05 Aug 2008 07:11:55 +0100</pubDate>
            <guid isPermaLink="false">1685744</guid>        </item>
        <item>
            <title>Patient characteristics and fairness</title>
            <link>http://www.medworm.com/index.php?rid=1670921&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm13mup18hkt72858%2F</link>
            <description>This study examines the fairness concept of health care professionals, and asks whether they are willing to use a patient’s
 age and other potential fairness characteristics rather than health benefits as relevant arguments in the allocation of health
 care resources? The patient characteristics in the health care professionals’ survey encompass age, productivity and lifestyle.
 The study is a replication of a much older study from the 1970s. The present study finds that the understanding of fairness
 among health care professionals differs from concepts of fairness in legislation. The status of various patient characteristics
 as rationing arguments has remained much the same, although nowadays health care professionals are expected to be more aware
 of moral dimensions and also legis...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1670921</comments>
            <pubDate>Wed, 30 Jul 2008 08:14:01 +0100</pubDate>
            <guid isPermaLink="false">1670921</guid>        </item>
        <item>
            <title>Can we assume that research participants are utility maximisers?</title>
            <link>http://www.medworm.com/index.php?rid=1670922&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd837kv7366175286%2F</link>
            <description>The objective of this study was to experimentally examine by means of an information manipulation if respondents are adhering
 to the utility theory axiom of utility maximisation. A repeated measure experimental design was used. Assessments were conducted
 pre- and post-intervention with self-administered questionnaires. The study participants were 158 (142 after exclusions) first
 year undergraduate students, Bangor University (UK). The intervention—information manipulation—did not induce the hypothesised
 changes in the perceived pros and cons of, or desire for, genetic testing and counselling for breast cancer; correlation revealed
 a weak relationship between the pros and cons of and desire for testing and counselling. We conclude that there was no evidence
 of utility maximisation...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1670922</comments>
            <pubDate>Wed, 30 Jul 2008 08:13:59 +0100</pubDate>
            <guid isPermaLink="false">1670922</guid>        </item>
        <item>
            <title>Guidelines for completing the EURONHEED transferability information checklists</title>
            <link>http://www.medworm.com/index.php?rid=1615164&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fq170383456521528%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The structure and methods to complete and derive a quality score from the European Network of Health Economic Evaluation Databases
 (EURONHEED) transferability information checklists for published economic evaluations were reported and discussed in a previous
 paper (Boulenger et al. in Eur J Health Econ 6, 334–346, 2005). Within the same paper, the use of the checklists was illustrated
 through their application to a sample of economic evaluations conducted in France and UK. The transferability information
 subchecklist, consisting of 16 items from the original 42-point checklist, and methods used to derive it, were validated among
 16 health economists across Europe participating in the EURONHEED project. Recent correspondence with other researchers, however,
 indic...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1615164</comments>
            <pubDate>Fri, 11 Jul 2008 06:55:40 +0100</pubDate>
            <guid isPermaLink="false">1615164</guid>        </item>
        <item>
            <title>The labor supply of registered nurses in Finland: the effect of wages and working conditions</title>
            <link>http://www.medworm.com/index.php?rid=1615165&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl12652w313421t4q%2F</link>
            <description>We examined both pecuniary and non-pecuniary
 factors that may be associated with nurses’ labor supply. We approximated a classical labor supply model and calculated the
 wage elasticities of hours of work and participation. Even though the wage elasticity was quite small, the effect on the hours
 supplied was significant. However, wages alone may not sufficiently increase the labor supply from the current stock of nurses;
 other elements, such as contractual conditions, seem to play an important role as well.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-008-0116-3Authors
		T. Kankaanranta, University of Tampere Tampere School of Public Health 33014 Tampere FinlandP. Rissanen, University of Tampere Tampere School of Public Health 33014 Tampere Finland
	

	
		J...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1615165</comments>
            <pubDate>Thu, 10 Jul 2008 07:25:00 +0100</pubDate>
            <guid isPermaLink="false">1615165</guid>        </item>
        <item>
            <title>Pricing and reimbursement of pharmaceuticals in Italy</title>
            <link>http://www.medworm.com/index.php?rid=1536321&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F93vr678637x74kh3%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;In Italy the price setting of medicines reimbursed by the National Health Service is regulated at the central level by AIFA,
 the national regulatory authority. Prices of non reimbursed medicines are indeed freely established, with some limitations,
 by pharmaceutical companies. To contain pharmaceutical expenditure and rationalise the whole sector the following measures
 have been introduced in the past years: a threshold to public pharmaceutical expenditure (PPE); a reference price system (RPS)
 for off-patent medicines; a pay-back mechanism as an alternative to price cut. In 2008 Italy launched a reform of the pharmaceutical
 expenditure governance system with the aim to introduce stability and promote development and competitiveness in the pharmaceutical
 sector.
 
...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1536321</comments>
            <pubDate>Fri, 20 Jun 2008 07:04:23 +0100</pubDate>
            <guid isPermaLink="false">1536321</guid>        </item>
        <item>
            <title>The income distributive implications of recent private health insurance policy reforms in Australia</title>
            <link>http://www.medworm.com/index.php?rid=1517947&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp3702g727h85374t%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The Australian government implemented a series of private health insurance (PHI) policy reforms between 1997 and 2000. As
 a result, the proportion of the population with PHI coverage increased by more than 35%. However, this study found significant
 evidence that the policy reform disproportionately favours high-income earners. In particular, the 30% premium subsidy represents
 a windfall gain for households which would have purchased PHI even without the rebate. The amount of such gain is estimated
 to be around $900 million per year, a large proportion of which went to higher income households.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-008-0111-8Authors
		Alfons Palangkaraya, The University of Melbourne Melbourne Institute of Applied Ec...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1517947</comments>
            <pubDate>Thu, 12 Jun 2008 06:24:36 +0100</pubDate>
            <guid isPermaLink="false">1517947</guid>        </item>
        <item>
            <title>Health technology assessment: for whom the bell tolls?</title>
            <link>http://www.medworm.com/index.php?rid=1507133&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fu361333hw68552w8%2F</link>
            <description>Content Type Journal ArticleCategory EditorialDOI 10.1007/s10198-008-0113-6Authors
		Livio Garattini, “Mario Negri” Institute for Pharmacological Research CESAV, Centre for Health Economics Ranica (Bg) ItalyGianluigi Casadei, “Mario Negri” Institute for Pharmacological Research CESAV, Centre for Health Economics Ranica (Bg) Italy
	

	
		Journal The European Journal of Health EconomicsOnline ISSN 1618-7601Print ISSN 1618-7598 (Source: The European Journal of Health Economics)</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1507133</comments>
            <pubDate>Tue, 10 Jun 2008 06:36:14 +0100</pubDate>
            <guid isPermaLink="false">1507133</guid>        </item>
        <item>
            <title>International comparison of orthotic brace prices</title>
            <link>http://www.medworm.com/index.php?rid=1493959&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm768x4117t371540%2F</link>
            <description>This study compared market prices (i.e. third-party reimbursement and patient co-payment) of prefabricated neck, wrist and
 knee braces in Belgium, France, the Netherlands, Ontario (Canada) and the UK. Data were collected through contacts with health
 authorities, health insurance funds, manufacturers and distributors. Market prices varied substantially between countries,
 indicating that manufacturers adapt their price setting strategy to the policy environment and the structure of the brace
 market of a country. Belgian prices tended to exceed prices in other countries for the selected neck, wrist and knee braces.
 There seems to be scope for reducing Belgian prices of selected braces.
 
	Content Type Journal ArticleCategory Original PaperDOI 10.1007/s10198-008-0112-7Authors
		Steven Sim...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1493959</comments>
            <pubDate>Tue, 03 Jun 2008 06:19:50 +0100</pubDate>
            <guid isPermaLink="false">1493959</guid>        </item>
        <item>
            <title>Pesticides and farmer health in Nicaragua: a willingness-to-pay approach to evaluation</title>
            <link>http://www.medworm.com/index.php?rid=1493960&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fdw621054m3j65193%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;A contingent valuation approach to assess the health effects of chemical pesticides among Nicaraguan vegetable farmers is
 presented. Farmers’ valuation of health is measured as their willingness to pay (WTP) for low-toxicity pesticides. Results
 show that farmers are willing to spend an additional amount of about 28% of current pesticide expenditure for avoiding health
 risks. The validity of results is established in scope tests and with a two-step regression model. WTP depends on farmers’
 experience with poisoning, income variables, and current exposure to pesticides. The results can help in designing rural health
 policies and in the formulation of programmes aiming to reduce the negative effects of pesticides.
 
	Content Type Journal ArticleCategory Original P...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1493960</comments>
            <pubDate>Tue, 03 Jun 2008 06:19:49 +0100</pubDate>
            <guid isPermaLink="false">1493960</guid>        </item>
        <item>
            <title>IQWiG: an opportunity lost?</title>
            <link>http://www.medworm.com/index.php?rid=1466709&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F935376262134m30m%2F</link>
            <description>Content Type Journal ArticleCategory EditorialDOI 10.1007/s10198-008-0109-2Authors
		Bengt Jönsson, Stockholm School of Economics Stockholm Sweden
	

	
		Journal The European Journal of Health EconomicsOnline ISSN 1618-7601Print ISSN 1618-7598 (Source: The European Journal of Health Economics)</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1466709</comments>
            <pubDate>Thu, 22 May 2008 05:52:54 +0100</pubDate>
            <guid isPermaLink="false">1466709</guid>        </item>
        <item>
            <title>Do quality-adjusted life years take account of lost income? Evidence from an Australian survey</title>
            <link>http://www.medworm.com/index.php?rid=1431470&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd2xmn14p24158442%2F</link>
            <description>This article reports the results of a study that
 questioned 131 respondents to a time trade-off (TTO) interview about their assumptions concerning consumption and the amount
 of thought given to consumption. Results indicate that, without prompting, most assumed unchanged consumption, implying little
 bias in existing studies.
 
	Content Type Journal ArticleCategory Original paperDOI 10.1007/s10198-008-0107-4Authors
		Jeff Richardson, Monash University Centre for Health Economics Building 75 Melbourne VIC 3800 AustraliaStuart J. Peacock, Monash University Centre for Health Economics Building 75 Melbourne VIC 3800 AustraliaAngelo Iezzi, Monash University Centre for Health Economics Building 75 Melbourne VIC 3800 Australia
	

	
		Journal The European Journal of Health EconomicsOnline ISSN 1...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1431470</comments>
            <pubDate>Tue, 06 May 2008 19:02:40 +0100</pubDate>
            <guid isPermaLink="false">1431470</guid>        </item>
        <item>
            <title>An economic evaluation of a perindopril-based blood pressure lowering regimen for patients who have suffered a cerebrovascular event</title>
            <link>http://www.medworm.com/index.php?rid=1414572&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F1uw605q43t527320%2F</link>
            <description>Conclusions&amp;nbsp;&amp;nbsp;This analysis demonstrates a cost-effective treatment for patients suffering a cerebrovascular event with a blood pressure
 lowering regimen. The findings of this study are in line with current decisions and guidance by the national institute for
 health and clinical excellence (NICE) in England.
 
 
 
	Content Type Journal ArticleCategory Original paperDOI 10.1007/s10198-008-0108-3Authors
		Manouchehr Tavakoli, University of St Andrews School of Management St Andrews KY16 9SS UKNeil Pumford, Nurseplus Ltd Auchterarder UKMark Woodward, Mount Sinai Medical School New York USAAlex Doney, Ninewells Hospital and Medical School Dundee UKJohn Chalmers, University of Sydney The George Institute Sydney AustraliaStephen MacMahon, University of Sydney The George Institute Sydn...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1414572</comments>
            <pubDate>Wed, 30 Apr 2008 07:27:02 +0100</pubDate>
            <guid isPermaLink="false">1414572</guid>        </item>
        <item>
            <title>The quality of life of Palestinians living in chronic conflict: assessment and determinants</title>
            <link>http://www.medworm.com/index.php?rid=1401862&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F31l5484772984j06%2F</link>
            <description>This study assessed the quality of life (QoL) of Palestinians living in conditions of chronic conflict and examined its determinants.
 An adapted World Health Organization quality of life (WHOQoL-Bref) instrument was used in a representative sample of 1,008
 adults. Factor analysis and multiple regression were conducted to determine associations between demographic and socioeconomic
 characteristics and scores of extracted principal determinants, and estimated overall and domain-specific QoL scores. Men,
 older persons and those less educated reported lower QoL than their counterparts. Negative associations were also found with
 higher distress and fear levels, and lower financial and freedom status. The chronic and entrenched conflict over generations
 resulted in lower QoL for the popula...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1401862</comments>
            <pubDate>Fri, 25 Apr 2008 09:09:29 +0100</pubDate>
            <guid isPermaLink="false">1401862</guid>        </item>
        <item>
            <title>A comparison between willingness to pay and willingness to give up time</title>
            <link>http://www.medworm.com/index.php?rid=1401861&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb50jp373616163w6%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;We compared the willingness-to-pay and willingness to give up time methods to assess preferences for digital subtraction angiography
 (DSA), computed tomography angiography (CTA) and magnetic resonance angiography (MRA). Respondents were hypertensive patients
 suspected of having renal artery stenosis. Data were gathered using telephone interviews. Both the willingness-to-pay and
 willingness to give up time methods revealed that patients preferred CTA to MRA in order to avoid DSA. The agreement between
 willingness-to-pay and willingness to give up time responses was high (kappa 0.65–0.85). The willingness-to-pay method yielded
 relatively more protest answers (12%) as compared to willingness to give up time (2%). So, our results provided evidence for
 the comparabil...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1401861</comments>
            <pubDate>Fri, 25 Apr 2008 09:09:29 +0100</pubDate>
            <guid isPermaLink="false">1401861</guid>        </item>
        <item>
            <title>Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany</title>
            <link>http://www.medworm.com/index.php?rid=1401863&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F11544r6x39513116%2F</link>
            <description>This study used a decision analytic model approach to evaluate the cost-effectiveness of linezolid versus vancomycin in the
 empirical treatment of complicated skin and soft-tissue infection (cSSTI) due to suspected methicillin-resistant Staphylococcus aureus (MRSA) from the German hospital and health care system perspective. Clinical probabilities were obtained from trial data,
 resource utilisation and MRSA prevalence rates were obtained through German physician interviews, and costs from published
 sources were applied to resource units. Outcomes included total cost/patient and cure. The estimated first-line cure rate
 for linezolid-treated patients was 90.1% versus 85.5% for vancomycin; total cure rates after two lines of treatment were 98.4%
 and 98.1%, respectively. Average total cos...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1401863</comments>
            <pubDate>Fri, 25 Apr 2008 08:10:30 +0100</pubDate>
            <guid isPermaLink="false">1401863</guid>        </item>
        <item>
            <title>The relationship between the Balanced Budget Act and length of stay for Medicare patients in US hospitals</title>
            <link>http://www.medworm.com/index.php?rid=1362184&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fb324w6508872763w%2F</link>
            <description>Conclusion&amp;nbsp;&amp;nbsp;This study is among the first to evaluate the impact of BBA and BBRA on hospital services. These acts had a negative effect
 on the ability of hospitals to continue offering safety-net services and negatively affected LOS.
 
 
 
	Content Type Journal ArticleCategory Original paperDOI 10.1007/s10198-008-0103-8Authors
		Mustafa Z. Younis, Jackson State University School of Health Sciences 350 West Woodrow Wilson Drive Jackson MS 39213 USADana A. Forgione, University of Texas at San Antonio College of Business One UTSA Circle San Antonio TX 78249-0632 USA
	

	
		Journal The European Journal of Health EconomicsOnline ISSN 1618-7601Print ISSN 1618-7598 (Source: The European Journal of Health Economics)</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1362184</comments>
            <pubDate>Tue, 08 Apr 2008 07:26:14 +0100</pubDate>
            <guid isPermaLink="false">1362184</guid>        </item>
        <item>
            <title>Cost utility analysis of knee prosthesis with complete microprocessor control (C-leg) compared with mechanical technology in trans-femoral amputees</title>
            <link>http://www.medworm.com/index.php?rid=1345889&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fqqrr5v3814234637%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The study determines the cost–utility of a unilateral electronic knee prosthesis (C-leg) compared to mechanical alternatives
 in trans-femoral amputees. For each type of prosthesis, 50 patients, treated in a major Italian centre, were enrolled. Quality
 adjusted life years (QALYs) were estimated from responses to EuroQol (EQ-5D). Healthcare and social costs were assessed for
 the estimated life cycle of the technologies (5&amp;nbsp;years). C-leg was associated with 0.09 more QALYs per patient per year (P&amp;nbsp;=&amp;nbsp;0.007). For the 5-year period, the incremental cost–utility ratio of C-leg resulted in &amp;#8364; 35,971 per QALY from the healthcare
 system perspective. If non-healthcare costs and productivity losses are included, the two groups to have similar costs (&amp;#8364...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1345889</comments>
            <pubDate>Tue, 01 Apr 2008 07:01:51 +0100</pubDate>
            <guid isPermaLink="false">1345889</guid>        </item>
        <item>
            <title>Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects</title>
            <link>http://www.medworm.com/index.php?rid=1345890&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fg79l05pu32634u43%2F</link>
            <description>Conclusion&amp;nbsp;&amp;nbsp;Based on the health-economic evaluation, the authors recommend the continuation of the general recommendation of PCV7 according
 to the 3&amp;nbsp;+&amp;nbsp;1 schedule within the German Statutory Health Insurance.
 
 
 
	Content Type Journal ArticleCategory Original paperDOI 10.1007/s10198-008-0098-1Authors
		Christa Claes, Leibniz University of Hannover Centre for Health Economics and Health System Research Hannover GermanyRalf René Reinert, University Hospital RWTH Aachen Institute of Medical Microbiology, National Reference Centre for Streptococci Aachen GermanyJohann-Matthias Graf von der Schulenburg, Leibniz University of Hannover Centre for Health Economics and Health System Research Hannover Germany
	

	
		Journal The European Journal of Health EconomicsOnline ISSN 1...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1345890</comments>
            <pubDate>Tue, 01 Apr 2008 07:01:49 +0100</pubDate>
            <guid isPermaLink="false">1345890</guid>        </item>
        <item>
            <title>Cost-effectiveness of hepatitis A immunization of children and adolescents in Germany</title>
            <link>http://www.medworm.com/index.php?rid=1331103&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm7025405243v2r47%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;
 Since hepatitis A has been largely eliminated as an endemic disease in Germany, the main risk of the disease now comes from
 holiday travel to countries with a high prevalence of hepatitis A. Starting from the age group specific new disease rate for
 the year 1998, a dynamic model is first drawn up of the effect of travel immunization against HAV in those aged 15–44 years,
 as the main group of travelers, and of the future demographic trends in Germany on the incidence trend over a study period
 of three times 10 years. An analysis is carried out of the epidemiological and economic significance of what is currently
 under discussion, i.e., additional group immunization of adolescents aged 11–15 years against hepatitis, in the same way as
 hepatitis B immunization,...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1331103</comments>
            <pubDate>Tue, 25 Mar 2008 19:07:05 +0100</pubDate>
            <guid isPermaLink="false">1331103</guid>        </item>
        <item>
            <title>International review of the utilisation and cost of percutaneous transluminal coronary angioplasty</title>
            <link>http://www.medworm.com/index.php?rid=1331102&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fd2x4x60m6240g782%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;
 We reviewed information published between 1990 and March 2001 to ascertain trends in the utilisation of percutaneous transluminal
 coronary angioplasty (PTCA) and to determine the availability of cost data. Our review encompassed Australia, Canada, France,
 Germany, Italy, Sweden, the United Kingdom, and the United States. The number of PTCAs increased in all countries studied
 during the 1990s. While the rate of PTCA use in all European countries lags behind that of the US, Germany and France are
 approaching the US rate, and the uptake of PTCA among European countries is increasing rapidly after a slow start. With regard
 to PTCA cost data, direct international comparisons are difficult since patient populations, methodological factors, and the
 timing and location ...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1331102</comments>
            <pubDate>Tue, 25 Mar 2008 19:07:05 +0100</pubDate>
            <guid isPermaLink="false">1331102</guid>        </item>
        <item>
            <title>The health care rationing debate: more clarity by separating the issues?</title>
            <link>http://www.medworm.com/index.php?rid=1331101&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F525342w112254715%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;
 The health policy debate about rationing is often confused by dealing with several different issues concurrently. This contribution
 introduces a typology and matrix that separates two of the most important of these issues in order to improve the clarity
 of the debate. The first of these issues, the mode of rationing, concerns how the responsible parties allocate scarce resources.
 This can be achieved non-systematically, for example, via ad hoc clinical bedside reasoning, or systematically with the aid
 of rigorously developed and tested algorithms, possibly including elucidated public preferences which trade-off efficiency
 and equity. The second issue, the transparency of the debate, concerns how the debate is presented, should it happen tacitly being left to the ...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1331101</comments>
            <pubDate>Tue, 25 Mar 2008 19:07:05 +0100</pubDate>
            <guid isPermaLink="false">1331101</guid>        </item>
        <item>
            <title>The role of prices in drug expenditure analysis</title>
            <link>http://www.medworm.com/index.php?rid=1331100&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw10518h072454k41%2F</link>
            <description>The objective of this article is to develop and apply several types of price indexes to the analysis of pharmaceutical expenditure
 to improve the way traditional indexes adjust for innovation in drug supply. The Laspeyres and Paasche indexes in the fixed
 and linked modalities were used. Price is defined as average expenditure at consumer price per daily defined dose (DDD). The
 empirical application is restricted to two therapeutic groups, antipsychotics and antidepressants, and to the pharmaceutical
 expenditure of the Catalan Health Service in the period 1991–1999. The indexes can be computed from the information currently
 recorded in the administrative procedures of health care insurers, or from sample information provided by regular market surveys.
 The proposed method allows for ...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1331100</comments>
            <pubDate>Tue, 25 Mar 2008 19:07:05 +0100</pubDate>
            <guid isPermaLink="false">1331100</guid>        </item>
        <item>
            <title>Analysis of costs and efficiency in general surgery specialties in the United Kingdom</title>
            <link>http://www.medworm.com/index.php?rid=1331099&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F6115j0648xw1334t%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;
 The UK government believes that substantial variations in efficiency persist in the National Health Service and has called
 for improvements in the cost effectiveness of service provision. As part of this general initiative, hospitals have been encouraged
 to participate in a project designed to compare labour costs in general surgery specialties. This paper analyses these costs,
 taking into account the scale of operation and mix of output, using econometric techniques and data envelopment analysis.
 The results produced by these methods are compared as a form of sensitivity analysis. For the majority of general surgery
 units no evidence is found to support the belief that there are widespread differences in cost efficiency. However, a small
 number of units appear ...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1331099</comments>
            <pubDate>Tue, 25 Mar 2008 19:07:05 +0100</pubDate>
            <guid isPermaLink="false">1331099</guid>        </item>
        <item>
            <title>Do physicians accept quality of life and utility measurement?</title>
            <link>http://www.medworm.com/index.php?rid=1331098&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe21734883537t151%2F</link>
            <description>This study investigates to what extent physicians accept quality of life (QoL) and economic utility measures as endpoints
 in clinical studies. It also explores who physicians think should value health states. As part of a European study three different
 physician groups were surveyed using a standardized mail questionnaire. These surveys were carried out by national random
 sample in Finland (rendering n=367) and by nonrandom samples in Austria (n=33), and Germany (n=41). Acceptance of utility measurement was classified by a four-level hierarchy. Knowledge of the QoL concept ranged between
 30% and 54% in the three samples. QoL was accepted by 72–90% of physicians, a summary index of QoL by 62–80%, its combination
 with duration by 51–68%, and quality-adjusted life years by 44–61%...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1331098</comments>
            <pubDate>Tue, 25 Mar 2008 19:07:05 +0100</pubDate>
            <guid isPermaLink="false">1331098</guid>        </item>
        <item>
            <title>Acknowledgement to referees</title>
            <link>http://www.medworm.com/index.php?rid=1331097&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fn250847175401705%2F</link>
            <description>Content Type Journal ArticleDOI 10.1007/s10198-001-0092-3Authors
		
	

	
		Journal The European Journal of Health EconomicsOnline ISSN 1618-7601Print ISSN 1618-7598
	
		Journal Volume Volume 2
	
		Journal Issue Volume 2, Number 4 / December, 2001 (Source: The European Journal of Health Economics)</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1331097</comments>
            <pubDate>Tue, 25 Mar 2008 19:07:05 +0100</pubDate>
            <guid isPermaLink="false">1331097</guid>        </item>
        <item>
            <title>Medical and economic evaluation of an integrated system of automated analysis in cellular hematology (Sysmex HST-330)</title>
            <link>http://www.medworm.com/index.php?rid=1331096&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx177h56132q26506%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;
 To assess the benefits of an integrated hematology system in the day-to-day running of a specialized university hospital laboratory
 the authors tested the Sysmex HST-330 system. Medical and economic evaluation sought to answer two questions: Does sample
 automation and use of such a system risk causing information loss prejudicial to patient care? Does it result in time-saving?
 The HST-330 was compared with the existing laboratory system by subjecting 1030 tubes to each work mode. With no loss of quality
 in medical results, the HST-330 provided an excellent technical base for the development of an expert system managing environmental
 data. The larger the batch, the more impressive was the performance of the HST-330 (0.86 min per specimen versus 1.04 min
 with the ...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1331096</comments>
            <pubDate>Tue, 25 Mar 2008 19:07:05 +0100</pubDate>
            <guid isPermaLink="false">1331096</guid>        </item>
        <item>
            <title>Ethics in medicine</title>
            <link>http://www.medworm.com/index.php?rid=1331109&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fk4476lv245030q50%2F</link>
            <description>&amp;nbsp;&amp;nbsp;
 Interdisciplinary and public debates, which may also include lay persons, can serve to develop and discuss basic principles.
 They help to take medical ethics closer to the patients and reduce the focus on experts. It should also be mentioned that
 such a highly differentiated field urgently needs an appropriate debating culture. It is also vital to introduce students
 and physicians to the thinking which underlies medical ethics and to accompany them through their entire professional lives
 by offering them the right courses. That these may not consist in the typical “learning” experience which normally dominates
 teaching is self-evident. It is absolutely necessary for the professionals in charge not only to take decisions in accordance
 with ethical principles but also...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1331109</comments>
            <pubDate>Tue, 25 Mar 2008 19:07:04 +0100</pubDate>
            <guid isPermaLink="false">1331109</guid>        </item>
        <item>
            <title>ISPOR: 3rd Annual European Conference</title>
            <link>http://www.medworm.com/index.php?rid=1331108&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fux038375q0004570%2F</link>
            <description>Content Type Journal ArticleCategory VariaDOI 10.1007/s101980100051Authors
		
	

	
		Journal The European Journal of Health EconomicsOnline ISSN 1618-7601Print ISSN 1618-7598
	
		Journal Volume Volume 2
	
		Journal Issue Volume 2, Number 1 / March, 2001 (Source: The European Journal of Health Economics)</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1331108</comments>
            <pubDate>Tue, 25 Mar 2008 19:07:04 +0100</pubDate>
            <guid isPermaLink="false">1331108</guid>        </item>
        <item>
            <title>Costs and quality of life in multiple sclerosis</title>
            <link>http://www.medworm.com/index.php?rid=1331107&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F4065k23408312763%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;
 We performed a cross-sectional, “bottom-up” observational study of resource use, costs, and quality of life in patients with
 multiple sclerosis (MS) in Germany. Six centers participated in the study. Patients were asked to complete a questionnaire,
 and a total of 737 patients returned it (response rate 66%). The questionnaire provided information on all resource consumption,
 medical, and nonmedical, work absence, informal care related to their MS, and quality of life (EuroQol). Simultaneously, medical
 charts were also abstracted for a subsample of 202 patients for comparison between answers in the questionnaires and registered
 data. Levels of disability were assessed using the Expanded Disability Status Scale. The mean age of the cohort was 41.9±14.1
 years ...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1331107</comments>
            <pubDate>Tue, 25 Mar 2008 19:07:04 +0100</pubDate>
            <guid isPermaLink="false">1331107</guid>        </item>
        <item>
            <title>A comparison of the EuroQol and the Health Utilities Index in patients treated for congenital anomalies</title>
            <link>http://www.medworm.com/index.php?rid=1331106&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fl5010008g2v868v1%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;
 It seems generally believed that the HUI3 is a more responsive utility measure than the EQ-5D because of the crude level structure
 of the EQ-5D compared to the HUI3. As empirical evidence to support this hypothesis is lacking, we undertook a study to compare
 the construct validity of the utility indices of the EQ-5Dindex and the HUI3index in 135 patients treated for congenital anorectal malformation and 57 patients treated for congenital diaphragmatic hernia.
 Discriminant validity was tested by the ability of the HUI3index and EQ-5Dindex to distinguish clinically relevant subgroups in the patient populations. Convergent validity was tested using Pearson correlations
 of the HUI3index and the EQ-5Dindex with the symptom scores. In general the index scores were in li...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1331106</comments>
            <pubDate>Tue, 25 Mar 2008 19:07:04 +0100</pubDate>
            <guid isPermaLink="false">1331106</guid>        </item>
        <item>
            <title>Introducing the new DRG-based payment system in German hospitals: a difficult operation?</title>
            <link>http://www.medworm.com/index.php?rid=1331105&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fc4806853067806v7%2F</link>
            <description>Summary&amp;nbsp;&amp;nbsp;
 Patient costs in German hospitals has until recently been calculated mainly by the length of hospital stay. However, in December
 1999 the Gesundheitsreform 2000 announced a dramatic change in the social laws. Starting in 2003 a prospective payment system
 will be introduced based on the classification of the “Australian refined diagnosis-related groups” (AR-DRG). DRGs are already
 used in many industrialized countries and are basically per case payment systems by group patients with homogeneous average
 costs based on the diagnoses and procedures performed in the hospital. When preparing for this new system, the clinician has
 substantial additional tasks. In addition to correctly documenting all clinical findings by the ICD-10 diagnoses and the German
 OPS301 pro...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1331105</comments>
            <pubDate>Tue, 25 Mar 2008 19:07:04 +0100</pubDate>
            <guid isPermaLink="false">1331105</guid>        </item>
        <item>
            <title>The reimbursable incontinence pads market for outpatients in five European countries</title>
            <link>http://www.medworm.com/index.php?rid=1331104&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv95795585420g816%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;
 This comparative study analyzed the domestic market for domiciliary incontinence pads in five European countries (Denmark,
 France, Germany, Italy, and the United Kingdom) according to a common scheme. National legislation, prescription procedures,
 delivery modalities, and the market situation were considered. The analysis involved reviewing the literature on incontinence
 devices in national and international journals and interviewing a selected expert panel of market operators in each country,
 composed of at least one civil servant, one physician, one distributor, and one manufacturer. No specific relationship was
 found between the health care system framework and the pads market, except for a greater inclination towards home care in
 national health services. In...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1331104</comments>
            <pubDate>Tue, 25 Mar 2008 19:07:04 +0100</pubDate>
            <guid isPermaLink="false">1331104</guid>        </item>
        <item>
            <title>The CHESME Health Economic Evaluations Database (CHESME HEED) project</title>
            <link>http://www.medworm.com/index.php?rid=1317406&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fx526r33l559m3516%2F</link>
            <description>Content Type Journal ArticleCategory EditorialDOI 10.1007/s10198-008-0099-0Authors
		Dimitrios Rovithis, National and Kapodistrian University of Athens Center for Health Services Management and Evaluation Papadiamantopoulou 123 115 27 Athens GreeceLycurgus Liaropoulos, National and Kapodistrian University of Athens Center for Health Services Management and Evaluation Papadiamantopoulou 123 115 27 Athens Greece
	

	
		Journal The European Journal of Health EconomicsOnline ISSN 1618-7601Print ISSN 1618-7598 (Source: The European Journal of Health Economics)</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1317406</comments>
            <pubDate>Wed, 19 Mar 2008 12:04:24 +0100</pubDate>
            <guid isPermaLink="false">1317406</guid>        </item>
        <item>
            <title>Redistributive effects in public health care financing</title>
            <link>http://www.medworm.com/index.php?rid=1313832&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fp78x347476782833%2F</link>
            <description>This article focuses on the redistributive effects of different measures to finance public health insurance. We analyse the
 implications of different financing options for public health insurance on the redistribution of income from good to bad health
 risks and from high-income to low-income individuals. The financing options considered are either income-related (namely income
 taxes, payroll taxes, and indirect taxes), health-related (co-insurance, deductibles, and no-claim), or neither (flat fee).
 We show that governments who treat access to health care as a basic right for everyone should consider redistributive effects
 when reforming health care financing.
 
	Content Type Journal ArticleCategory Original paperDOI 10.1007/s10198-008-0100-yAuthors
		Ivonne Honekamp, University of Bam...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1313832</comments>
            <pubDate>Tue, 18 Mar 2008 08:14:30 +0100</pubDate>
            <guid isPermaLink="false">1313832</guid>        </item>
        <item>
            <title>Comparing methodologies for the cost estimation of hospital services</title>
            <link>http://www.medworm.com/index.php?rid=1307467&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fe30h28604112v562%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The aim of the study was to determine whether the total cost estimate of a hospital service remains reliable when the cost
 components of bottom-up microcosting were replaced by the cost components of top-down microcosting or gross costing. Total
 cost estimates were determined in representative general hospitals in the Netherlands for appendectomy, normal delivery, stroke
 and acute myocardial infarction for 2005. It was concluded that restricting the use of bottom-up microcosting to those cost
 components that have a great impact on the total costs (i.e., labour and inpatient stay) would likely result in reliable cost
 estimates.
 
	Content Type Journal ArticleCategory Original paperDOI 10.1007/s10198-008-0101-xAuthors
		S. S. Tan, Erasmus MC University Medical Center...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1307467</comments>
            <pubDate>Fri, 14 Mar 2008 07:29:05 +0100</pubDate>
            <guid isPermaLink="false">1307467</guid>        </item>
        <item>
            <title>SF-6D versus EQ-5D: reasons for differences in utility scores and impact on reported cost-utility</title>
            <link>http://www.medworm.com/index.php?rid=1293894&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F313w74282v2p8172%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;The choice of instrument (e.g. EQ-5D vs. SF-6D) can lead to different health-related utility scores, but it is unclear why
 these differences arise and whether they change cost utility analysis (CUA) results. This paper addresses these issues using
 a case study where using SF-6D rather EQ-5D led to greater utility gain and a lower cost per QALY for treatment. The paper
 examines reasons for this difference. This paper finds that an important factor was the inclusion in the SF-6D descriptive
 system of separate items for “vitality” and “social functioning”, not explicitly included in EQ-5D. Further studies are required
 that examine the impact of the choice of instrument on cost-utility.
 
	Content Type Journal ArticleCategory Original paperDOI 10.1007/s10198-00...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1293894</comments>
            <pubDate>Sun, 09 Mar 2008 06:54:15 +0100</pubDate>
            <guid isPermaLink="false">1293894</guid>        </item>
        <item>
            <title>Expenditure on health care in the EU: making projections for the future based on the past</title>
            <link>http://www.medworm.com/index.php?rid=1249918&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fv6m171181rw0r220%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;
 Health expenditure in the countries of the European Union has risen faster than gross domestic product (GDP) since 1970, namely
 by 3.2 percentage points in the 1970s, 0.8 in the 1980s, and 1.2 in the 1990s. When examining factors responsible for health
 expenditure, the “usual suspects”– which are reviewed in turn – are: demography/ageing, economic growth/rising GDP, health
 care resources, new technologies and medical progress, and health care system design (especially Bismarck vs. Beveridge).
 While the impact of ageing is usually overestimated, medical progress will continue to exert its impact on spending. If future
 health care expenditure will rise faster than GDP by 1 percentage point, the EU average will increase from 8.6% in 1998 to
 11.8% in 2030. I...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1249918</comments>
            <pubDate>Wed, 20 Feb 2008 22:53:18 +0100</pubDate>
            <guid isPermaLink="false">1249918</guid>        </item>
        <item>
            <title>Health-related quality of life of patients with overactive bladder receiving immediate-release tolterodine</title>
            <link>http://www.medworm.com/index.php?rid=1249917&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fm2gj106760368660%2F</link>
            <description>In conclusion, many aspects of HRQOL, as measured by the KHQ, significantly improved with tolterodine IR treatment.
 These HRQOL improvements were consistent with clinical efficacy results. The findings demonstrate that tolterodine IR patients
 experience overall improvement in their condition that resulted in important impacts on their HRQOL.
 
 
 
	Content Type Journal ArticleCategory Original PapersDOI 10.1007/s101980100064Authors
		A.M. Pleil, Pharmacia Limited, High Wycombe, UK GBP.R. Reese, Strategic Outcomes Services of CareScience, Inc., Research Triangle Park, N.C., USA USC.J. Kelleher, Guy's and St. Thomas' Hospital Trust, London, UK GBG.J. Okano, Strategic Outcomes Services of CareScience, Inc., Research Triangle Park, N.C., USA US
	

	
		Journal The European Journal of Health E...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1249917</comments>
            <pubDate>Wed, 20 Feb 2008 22:53:18 +0100</pubDate>
            <guid isPermaLink="false">1249917</guid>        </item>
        <item>
            <title>18th Annual Conference of the EuroQol-Group in Copenhagen September 2001</title>
            <link>http://www.medworm.com/index.php?rid=1249916&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F5447vu1p1jt27731%2F</link>
            <description>Content Type Journal ArticleCategory Meeting reportDOI 10.1007/s10198-001-0081-6Authors
		W. Greiner, Hannover DE
	

	
		Journal The European Journal of Health EconomicsOnline ISSN 1618-7601Print ISSN 1618-7598
	
		Journal Volume Volume 2
	
		Journal Issue Volume 2, Number 4 / December, 2001 (Source: The European Journal of Health Economics)</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1249916</comments>
            <pubDate>Wed, 20 Feb 2008 22:53:18 +0100</pubDate>
            <guid isPermaLink="false">1249916</guid>        </item>
        <item>
            <title>How to define a basic package of health services for a tax funded or social insurance based health care system?</title>
            <link>http://www.medworm.com/index.php?rid=1249915&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fdg485n2213145583%2F</link>
            <description>Content Type Journal ArticleCategory EditorialDOI 10.1007/PL00012219Authors
		F. Rutten, Institute for Medical Technology Assessment, Erasmus University Rotterdam, The Netherlands NLJ. van Busschbach, Institute for Medical Technology Assessment, Erasmus University Rotterdam, The Netherlands NL
	

	
		Journal The European Journal of Health EconomicsOnline ISSN 1618-7601Print ISSN 1618-7598
	
		Journal Volume Volume 2
	
		Journal Issue Volume 2, Number 2 / June, 2001 (Source: The European Journal of Health Economics)</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1249915</comments>
            <pubDate>Wed, 20 Feb 2008 22:53:18 +0100</pubDate>
            <guid isPermaLink="false">1249915</guid>        </item>
        <item>
            <title>Pharmaceutical pricing and reimbursement in Finland</title>
            <link>http://www.medworm.com/index.php?rid=1249914&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2Fw6113n4465165471%2F</link>
            <description>Abstract&amp;nbsp;&amp;nbsp;
 The cornerstones of social security within the Finnish health care system are public health care and an insurance system covering
 drug costs in outpatient care and the services of the private health care sector. The reimbursement system is two-tiered,
 so that when a wholesales price is approved for a drug, it automatically enters the basic reimbursement category. The acceptance
 of a medicine into the higher reimbursement categories for serious and long-term illnesses involves a separate legislative
 process. Compared with OECD countries, the degree of reimbursement is low. The price decision is mainly based on international
 price comparisons, the price of corresponding products on the market, and the funds the reimbursement system has at its disposal.
 Since 1998,...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1249914</comments>
            <pubDate>Wed, 20 Feb 2008 22:53:18 +0100</pubDate>
            <guid isPermaLink="false">1249914</guid>        </item>
        <item>
            <title>Health care costs, work productivity and activity impairment in non-malignant chronic pain patients</title>
            <link>http://www.medworm.com/index.php?rid=1217677&amp;cid=s_33421_51_f&amp;fid=33421&amp;url=http%3A%2F%2Fwww.springerlink.com%2Fcontent%2F403t5k65535621l5%2F</link>
            <description>This study explores the costs of non-malignant chronic pain in patients awaiting treatment in a multidisciplinary pain clinic
 in a hospital setting. Health care costs due to chronic pain are particular high during the first year after pain onset, and
 remain high compared with health care costs before pain onset. The majority of chronic pain patients incur the costs of alternative
 treatments. Chronic pain causes production losses at work, as well as impairment of non-work activities.
 
	Content Type Journal ArticleCategory Original paperDOI 10.1007/s10198-008-0096-3Authors
		Christian Kronborg, University of Southern Denmark Institute of Public Health, Health Economics Unit J.B. Winsløwsvej 9B 5000 Odense C DenmarkGitte Handberg, Odense University Hospital Funen County Multidisciplinary...</description>
            <author>The European Journal of Health Economics</author>
            <type>journals</type>
        <comments>http://www.medworm.com/rss/comments.php?id=1217677</comments>
            <pubDate>Thu, 07 Feb 2008 17:56:26 +0100</pubDate>
            <guid isPermaLink="false">1217677</guid>        </item>
    </channel>
</rss>
